Studies on the role of autoantibodies and autoantigens in rheumatoid arthritis and myositis by Cerqueira, Cátia
From DEPARTMENT OF MEDICINE, SOLNA 
Karolinska Institutet, Stockholm, Sweden 
STUDIES ON THE ROLE OF 
AUTOANTIBODIES AND AUTOANTIGENS 
IN RHEUMATOID ARTHRITIS AND 
MYOSITIS 
Cátia Soraia Fernandes Cerqueira 
 
Stockholm 2016 
 
 Cover image by Filipe Brito 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by AJ E-print AB 
© Cátia Soraia Fernandes Cerqueira, 2016 
ISBN 978-91-7676-154-0 
Studies on the role of autoantibodies and autoantigens in 
rheumatoid arthritis and myositis  
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen 
försvaras i CMM lecture Hall, L8:00 
 
Tuesday 1
st
 March, 2016 at 9:00 o’clock 
 
By 
Cátia Soraia Fernandes Cerqueira 
Principal Supervisor: 
Professor Per-Johan Jakobsson 
Karolinska Institutet 
Department of Medicine, Solna 
Rheumatology Unit 
 
Co-supervisor(s): 
Assistant Professor Karin Lundberg 
Karolinska Institutet 
Department of Medicine, Solna 
Rheumatology Unit 
 
PhD Elena Ossipova 
Karolinska Institutet 
Department of Medicine, Solna 
Rheumatology Unit 
Opponent: 
Professor Antony Rosen 
Johns Hopkins University School of Medicine, USA 
Department of Medicine 
Division of Rheumatology 
 
Examination Board: 
Professor Anders Bengtsson  
Lund University 
Department of Clinical Sciences 
Division of Rheumatology 
 
Professor Jan Kihlberg  
Uppsala University 
Department of Chemistry, BMC, Physical Organic 
Chemistry 
 
Associate professor Lisa Westerberg 
Karolinska Institutet 
Department of Microbiology, Tumor and Cell biology 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Para ser grande sê inteiro: nada 
Teu exagera ou exclui. 
Sê todo em cada coisa. Põe quanto és 
 No mínimo que fazes. 
Assim em cada lago a lua toda 
 Brilha, porque alta vive” 
 
Ricardo Reis, heterónimo de Fernando Pessoa 
  
  
 ABSTRACT 
A major population of patients affected with rheumatoid arthritis (RA) and inflammatory 
idiopathic myopathies (IIM, collectively called myositis) is characterized by the presence of 
autoantibodies. The pathogenic impact of anti-citrullinated protein/peptide (ACPA) or anti-
histidyl transfer RNA synthetase (HisRS; Jo1) autoantibodies remains largely unknown. The 
aims of the thesis were to understand the molecular mechanisms underlying the autoimmune 
component (specifically, the auto-antibody and -antigen dynamics) in RA and myositis; and 
to develop ACPA neutralizing compounds. 
Paper I: Purified anti-cyclic citrullinated peptide antibodies (aCCP2 IgG) were estimated to 
represent ~2% of the total RA IgG pool, and demonstrated to display distinct and individual 
reactivities against citrullinated epitopes from fibrinogen, collagen type II, α-enolase and 
vimentin. In-vivo generated autoantigens in synovial tissue and fluid were recognized by 
aCCP2 IgG. 
Paper II: Anti-CCP2 IgG purified according to the methodology described in paper I were 
injected in mice and shown to induce pain-like behaviour. The underlying molecular 
mechanism appears to be chemokine-dependent because 1) aCCP2 IgG promoted activation 
of murine osteoclasts with generation of CXCL1 (human IL-8); 2) aCCP2 IgG stained CD68-
bearing macrophages/osteoclasts, closely localized to the calcitonin gene related peptide 
(CGRP)-positive sensory nerve fibers; 3) reparixin, a CXCL1/2 receptor antagonist, blocked 
aCCP2 IgG induced pain. 
Papers III and IV: Endogenously citrullinated fibrinogen peptides were found to be 
recognized by a large portion of sera from the Epidemiological Investigation of RA (EIRA) 
cohort. CCP2+ RA sera displayed 65% and 15 % immune reactivity against peptides from the 
fibrinogen α chain Cit573 (563-583) and Cit591 (580-600), respectively. Peptides from the β 
chain, Cit72 (62-81) and Cit74 (62-81), were recognized by 35% and 53% of the CCP2+ RA 
patients. The same fibrinogen peptides were shown to in vitro individually bind and block 
purified aCCP2 IgG in a dose-dependent manner, displaying a maximum of 83% blockade. 
Approximately 90% autoantibodies were neutralized by Cit573 and Cit591 combined, and 
further improvement of the blocking capacity was registered (>90%) when incubating aCCP2 
IgG with a cyclic version of Cit573. 
Since the peptide Cit573 (also termed [Cit573]fib(563-583)) showed the best inhibition 
percentage, a truncated version was inserted into the stable framework sunflower trypsin 
inhibitor-1 (SFTI-1, and denoted s1[Cit573]fib(566-580)). This compound showed enhanced 
blocking capacity, 79% antibodies were neutralized with an estimated IC50 of 20 µM, in 
comparison to the linear counterparts (73% maximum inhibition with the IC50:s ranging from 
59 to 123 µM). Stability in blood was also improved, with above 90% of s1[Cit573]fib(566-
580) remaining after five hours, whereas the cyclic and linear counterparts were degraded 
after one hour. Using a mutant of s1, s2[Cit573,Arg575]fib(566-580), anti-[Cit573]fib(563-
583) IgG (aCit573 IgG) were purified from RA plasma and estimated to comprise 0.33% of 
the total RA IgG pool. Binding affinity measurements demonstrated that aCit573 IgG bind 
 the mutant scaffold peptide s3[Cit573,Arg575]fib(566-580) with high affinity (Kd = 2 nM). 
Thus, subsets of ACPA recognizing citrullinated fibrinogen epitopes appear to be of high 
affinity. 
Paper V: The cytoplasmic autoantigen HisRS was found in extracellular compartments 
(bronchoalveolar lavage, BAL, sera and plasma). High circulating levels of HisRS were 
found in myositis, and further increased in anti-HisRS+ patients; significant levels of HisRS 
were also detected in healthy individuals, whereas anti-HisRS IgG, IgA and IgM 
autoantibodies were only detected in sera and BAL from patients with myositis. In addition, 
anti-TRIM21 IgG were also identified in myositis BAL, positively correlating with the 
presence of anti-HisRS IgG. A so far uncharacterized factor in BAL of myositis patients was 
found to bind exogenous HisRS. In experiments addressing platelet activation, HisRS was 
found to trigger platelet activation in a dose-response dependent manner at low picomolar 
concentrations. 
In conclusion, the development of a methodology to isolate autoantibodies from RA patients’ 
plasma, serum and synovial fluid, provided opportunities to address the pathogenic role of 
ACPA. Purified aCCP2 IgG induced pain-like behaviour, raising a possible mechanism for 
the pain RA patients occasionally feel before clinical onset of disease or after being 
medicated and in remission. A stable, high affinity anti-citrullinated fibrinogen autoantibody 
blocking compound was designed and we propose ACPA neutralization with fibrinogen-
derived peptides as a complimentary treatment strategy for ACPA+RA. ACPA pain mediated 
effect may also be a functional target, amenable for blocking. The presence of HisRS 
extracellularly suggests novel and so far undescribed functions, which merits further 
investigations. Finally, a possible coupled immune response among HisRS and TRIM21 in 
lungs of myositis patients provides new clues for the development of autoimmunity in 
myositis and the associated anti-synthetase syndrome. 
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INTRODUCTION 
The immune system has evolved to protect our body from potential threats such as microbes, 
viruses and parasites. It encompasses an orchestra of components that should be in 
homeostasis in order not to react to self-molecules and simultaneously should be able to 
defend us from external threats. Occasionally, reactions to self-components arise and chronic 
inflammation develops leading to pathogenic autoimmune diseases. From an evolutionary 
perspective chronic autoimmune inflammatory diseases are considered to be fairly new in 
history because the life expectancy of our ancestors was shorter. However, in the present 
time, ~5% of the world population suffers from autoimmune disorders which increases the 
burden of such ailments (1-5). This PhD thesis intends to provide additional knowledge to the 
mechanisms that govern a pathogenic autoimmune state and suggests new approaches for the 
treatment of conditions such as rheumatoid arthritis and myositis. 
 
1. Innate immunity 
The immune system employs several different mechanisms that aim at protecting the host 
from invading pathogens. The first lines of defense pathogens encounter when attempting to 
invade the host are physical and biochemical barriers such as skin, lung, gut, eyes, nose and 
oral cavity (6). When pathogens invade such obstacles, tissue-resident macrophages, 
dendritic cells (DC), and to some extent mast cells are the first elements encountered (7-9). 
Upon stimulation, and with the purpose to clear away the invading agent, the resident innate 
immune cells phagocyte the pathogen and produce an array of inflammatory mediators 
such as: cytokines (e.g. tumor necrosis factor α, TNF-α; interleukin (IL) 1, IL-1 and IL-6) 
(10, 11), chemokines (e.g. chemokine C-C motif ligand 2, CCL2 and chemokine CXC motif 
ligand 8, CXCL8) (12, 13), eicosanoids and vasoactive amines (14). The inflammatory 
mediators released lead to increased vasodilation and permeability of the endothelia which in 
turn facilitates the passage of recruited neutrophils and monocytes into the infection site. The 
endothelial cells increase the expression of cell-adhesion molecules that support leucocytes 
adherence, hence promoting the passage through the blood vessel to the infected site (15-19). 
The accumulation of these inflammatory cells, serum proteins (e.g. complement system, C-
reactive protein) and fluid into the infected tissue leads to increase heat, redness, swelling, 
and pain which translates the initiation of the inflammatory response. When the inflammatory 
process is not properly resolved it may lead to chronic inflammation, a characteristic feature 
of rheumatoid arthritis (RA) for example. 
Macrophages, DC as well as neutrophils utilize soluble and membrane-bound receptors that 
recognize pathogenic-associated molecular patterns (PAMPs), not present in the host like: 
Toll-like receptors, nucleotide-binding oligomerization domain-like receptors, cytosolic 
retinoic-acid inducible gene-I, C-reactive protein, mannose binding lectin and C-type lectin 
receptors (6, 20-22). The usage of receptors that recognize PAMPs enables the innate 
immune system to recognize different pathogens and further permits the distinction 
between self and non-self structures (23, 24). 
 
Cell infection by viruses is typically characterized by the production of a group of 
cytokines termed interferons (IFNα and IFN). Plasmacytoid dendritic cells (pDC, a 
different type of DC also involved in recognition of pathogens, specifically viruses, and 
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induction of primary immune response) produce higher levels of IFN in comparison to 
other cell types. The expression of TLR7 and TLR9 (internal sensors of viral nucleic acids) 
contributes to pDC efficiency at secreting IFN. IFNα and IFN are secreted by virus-
infected cells and will generate a status of virus-resistance in uninfected host cells by 
impairing the capacity of the virus to replicate within the cell. By inducing the expression 
of major histocompability complex (MHC) I molecules in non-infected cells, IFN promotes 
resistance of those cells to viral infection. In addition, and also through a MHC-I related 
mechanism, IFN renders the newly infected cells increased susceptibility to cytotoxic 
lymphocytes (CD8 T cells) and thereby to be killed. IFN is also capable of activating 
natural killer (NK) cells that will consequently eliminate the virus-infected cells (25-28). 
 
Natural killer cells are considered part of the innate immune system, although being derived 
from a common lymphoid progenitor as other lymphocytes (B and T cells). IFN and 
macrophages-derived cytokines induce NK cells activation, thus, NK cells are also very 
important for restraining viral infections at an early stage. NK cells bind viral-infected and 
tumor cells through specific surface receptors and once bound induce cell death by releasing 
cytotoxic granzymes and perforin(s). NK cells were recently described to also respond to 
bacteria-infected cells (29-32). 
 
Platelets are involved in blood clotting which generates a physical barrier that avoids the 
spread of the infection. They rapidly move to the site of infection and accumulate in abundant 
number. Platelets express several innate immunity related receptors (e.g. TLR), act as 
granulocytes releasing anti-microbial substances and secrete inflammatory mediators 
important in the first stage of the inflammatory process (33). 
 
Recent research showed the presence of tissue-resident T cells (e.g. innate lymphoid cells) 
which together with macrophages and DC continuously patrol the body for external threats. 
These cells participate in immune-regulation, repair and homeostasis (34). T cells were also 
shown to be present in healthy human skin, upholding immune surveillance (35). 
 
2. Acquired immunity 
When pathogens escape innate immunity, the host defense recruits more specialized 
components and the adaptive immune response (or acquired immunity) is initiated. At this 
point the innate immune system is crucial in order to make the transition to acquired 
immunity. B cells, macrophages and especially DC are ‘professional’ antigen presenting 
cells (APC) that bridge the two immune responses/immunities. Memory (capacity to, upon a 
new encounter, respond to the same antigen more rapidly and effectively) and specificity to 
antigens are important characteristic of the adaptive immunity. T and B cells are key players 
at this point since they express highly variable antigen specific receptors (T cell receptor, 
TCR and B cell receptor, BCR). The diversity of TCR and BCR available to recognize a wide 
range of antigens is achieved through gene rearrangements. Each lymphocyte recognizes one 
antigen that has been taken up by APCs at the site of infection and presented in secondary 
lymphoid organs. Upon encounter with the antigen, lymphocytes rapidly proliferate and 
produce a large number of cells of certain specificities (clones) capable of mounting an 
immune response against that particular antigen (clonal selection) (22). Certain cells of these 
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clones further differentiate into memory cells, capable of rapidly and efficiently respond to a 
secondary encounter. 
 
2.1. T cells 
Antigen presenting cells engulf and process antigens which will be presented to CD4
+
 T cells 
through the MHC class II using the CD4 molecule as a coreceptor stabilizing the interaction. 
On the other hand, CD8
+
 T cells are activated by MHC class I molecules presenting virally 
transcribed antigens or intracellular components, using the CD8 molecule as a coreceptor. T 
cells are generated in the bone marrow and migrate to the thymus for maturation into naïve 
CD4
+
 or CD8
+
 T cells. Thereafter, T cells circulate to secondary lymph nodes where they 
encounter APC expressing cognate MHC-peptide complexes. Each T cell of a particular 
clone expresses one specific TCR that will bind one specific pathogen-derived peptide 
presented by an MHC-molecule on the APC. Upon antigen presentation, and depending on 
the cytokine milieu, T cells will differentiate into different subsets, which in turn will secrete 
different effector cytokines and perform distinct biological functions. Mature DCs, which 
have encountered PAMPs and presented the antigens to T cells, also express surface co-
stimulatory molecules important for an effective T cell proliferation and differentiation. Some 
examples of T cell populations are T helper (TH) cells such as TH1, TH2 and TH17, cytotoxic 
T cells, and regulatory T cells (T reg) (22, 24, 36, 37). B cells need T cell help to become 
activated in order to produce antibodies for the host defense. TH cells also provide signals for 
improvement of macrophages phagocytosis capacity. After the antigen has been eliminated a 
group of T cells remains (memory T cells) providing long lasting immunity (38-43).  
 
2.2. B cells 
B cells are produced in the bone marrow (where they undergo selection) and are further 
matured in secondary lymphoid organs. Mature B cells are divided in three main 
subgroups: follicular B cells, B1 cells and marginal zone B cells. The three subsets have 
different locations, cell surface markers, antigen specificity and threshold for activation. 
Marginal zone (MZ) B cells are located in the spleen and act on blood-borne pathogens. 
The antibodies secreted by MZ-derived plasma cells display low affinity to the antigens. B1 
B cells are found in the peritoneal and pleural cavities and in mucosal sites where they 
survey environmental-derived pathogens. Both MZ B cells and B1 B cells have the capacity 
to respond in a T-cell independent way. The most abundant subset of B cells is the 
population of follicular B cells that migrate to lymphoid tissues and upon antigen 
encountering and interaction with T follicular helper cells and follicular dendritic cells will 
form germinal centers (GC). During this process, antigen B cell receptors undergo somatic 
hypermutation (SHM) and Immunoglobulin (Ig) isotype class-switch recombination (ICSR) 
and ultimately differentiate into high-affinity long-lived antibody-secreting cells (plasma 
cells) or memory B cells. Memory B cells are important to initiate the secondary immune 
response. Upon meeting the same antigen memory B cells drive a faster and more efficient 
response, producing high affinity antibodies (22, 37, 44, 45). 
 
The processes of V(D)J recombination (V, variable; D, diversity; J, joining gene segments), 
SHM and ICSR during BCR maturation are important to produce highly diverse antibodies 
with improved affinity to respond to antigens. This diversity is acquired through two main 
4 
 
stages: first, BCR diversity takes place in the bone marrow in an early stage of B cell 
development and independent of antigen. During this period recombination of V(D)J 
segments of the heavy (H) and light (L) chain occurs. The heavy chain is assembled by 
recombination of the JH and DH segments, followed by JHDH-VH rearrangement. 
Subsequently, the light chain is produced by recombination of VJ segments. Upon VDJ 
rearrangement immature B cells express heavy chain of µ type, which leads to expression 
of IgM on the surface and subsequently, mature B cells express heavy chains of µ and  
type leading to IgM and IgD appearance on the surface. Recombination-activating genes 
(RAG) 1/2 are important mediators of V(D)J genes rearrangement. In addition, the enzyme 
terminal deoxynucleotidyl transferase adds extra diversity by inserting nucleotides between 
VH and DH and between DH and JH junctions. The secondary source of diversity that gives 
rise to antibodies with multiple reactivities occurs in an antigen and T cell-dependent 
manner once immature B cells have migrated from the bone marrow to the spleen, lymph 
nodes and other lymphoid tissues. The follicular B cells that present higher affinity for the 
antigen will generate germinal centers (GC). Within the GC somatic hypermutation 
(SHM) takes place whereby point mutations are inserted into the rearranged variable 
regions of the BCR. These mutations influence the avidity and specificity for the antigens. 
The B cells expressing high-affinity BCR after SHM survive and differentiate into memory 
B cells or long-lived plasma cells, which will eventually secrete high affinity antibodies. 
Immunoglobulin (Ig) isotype class-switch recombination (ICSR) is an important process 
employed to further diversify the antibody repertoire in an immune response. During class 
switch recombination the original constant region (C) of the BCR (Cµ, IgM) is substituted 
by the constant region of a different isotype (C, Cα and Cε).Thus, the isotype of the 
substituted heavy chain C region will dictate the antibody class (IgG, IgA or IgE) produced 
and therefore the effector function it entails (Figure 1, Table 1) (6, 22, 45, 46). Similarly to 
the initial gene rearrangement of the BCR which is dependent of RAG, SHM and class 
switching are dependent of the expression of activation-induced cytidine deaminase (AID) 
in activated B cells. Throughout these maturation processes B cells undergo tolerance 
checkpoints whereby anti-self reactivity is eliminated (Figure 2). 
 
2.3. Antibodies 
Antibodies are tetramers composed of two light chains (L) and two heavy chains (H, Figure 
1). The variable domain (V) of an antibody contains hypervariable complementary 
determining regions, important for antigen specificity and variety. The antigen binding sites, 
located in the variable domains, adapt to the three dimensional structure of an antigen when 
both parts come in contact. Antigen and antibody are complementary to each other and 
connect through non-covalent bonds, i.e., van Der Waals, hydrophobic and electrostatic 
interactions and hydrogen bonds. The constant regions of the heavy chain and light chain 
determine the isotype and sub-class of the antibody. The different antibody classes are listed 
in Table 1 and the basic structure of an antibody is illustrated in Figure 1 (6, 47). 
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Figure 1 Basic structure of an antibody. The typical structure 
of an antibody allows it to perform two functions: 
recognition/binding of antigens by the variable domains VL and 
VH, and engagement of several immune effector functions 
through binding of the Fc part to Fc receptors on other cells 
(e.g. phagocytes, NK and T cells) and via binding and 
activation of the first component of the complement system 
(C1q). The four polypeptide chains are united through disulfide 
bridges and the tertiary structure is kept by covalent bonds and 
non-covalent interactions. C, constant; V, variable; L, light; H, 
heavy; Fc, fragment crystallizable region; Fab, fragment antigen-binding. 
 
Table 1 Antibody classes and corresponding characteristics. 
Isotypes Structure Characteristics 
IgG 
 
IgG is divided in four subclasses (IgG1-4) and constitutes ~75% of 
total serum Igs. The average concentrations for each subclass in 
circulation are 9, 3, 1 and 0.5 mg/mL, respectively. Molecular 
weights vary between 146-170 kDa. The half-life of IgG1 and 4, 2, 
and 3 is 21, 20 and 7 days, respectively. 
IgA 
 
IgA predominantly exists in mucosal surfaces (70-95%) but 
constitutes 15-20% of serum Ig. It can exist as monomers (IgA1 and 
2, 160 kDa) or as a dimer (secretory IgA, 385 kDa). IgA1 is the most 
abundant subclass (3 mg/mL), followed by IgA2 (0.5 mg/mL) and 
secretory IgA (0.02 mg/mL). The half-life of IgA is 6 days.  
IgM 
 
IgM constitutes ~10% total Ig pool and is usually secreted as a 
pentamer of 970 kDa (1.5 mg/mL). It is the first antibody to be 
generated during B cell development. The half-life of IgM is 10 
days. 
IgE 
 
IgE is a monomeric Ig of 188 kDa that binds with high affinity to 
specific Fc receptors on basophils and mast cells via its Fc-part. It is 
involved in allergic reactions and protection against helminth 
parasites. Serum concentration is below <0.05 µg/mL and the half-
life is 2 days. 
IgD 
 
IgD constitutes <1% total serum Igs. A transmembrane monomeric 
form (184 kDa) can be found in mature naïve B cells and it acts as an 
antigen-specific receptor. With an average concentration of 30 
µg/mL its half-life is 3 days. 
 
Antibody-antigen interactions are reversible. The strength of the bond between them is 
defined as affinity and by applying the Law of Mass action (model 1:1, antigen:antibody) it 
is possible to determine how strong the bond is. The Law of Mass action states: 
 
 
 
The affinity of an antibody is translated by the dissociation constant K given in Molar units, 
at equilibrium. The closer K is to zero, the higher the affinity. Antibodies with K < 10
-7
 M are 
said to bind antigens with high affinity, whereas antibodies with K > 10
-7
 M are considered 
low affinity. Although the binding affinity is commonly used to describe these types of 
interactions, antibodies contain two or more antigen binding sites and antigens are usually 
multivalent, therefore the term avidity (which considers antibody and antigen valence) is a 
[Antibody] + [Antigen] K
   
= [Antibody x Antigen] 
[Antibody x Antigen] 
[Antibody][Antigen] 
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more accurate and relevant approach to define the binding strength. This concept requires 
more advanced mathematical models (6, 45, 48). 
 
Plasma-cell secreted antibodies remove and destroy pathogens by modulating immune 
functions through a variety of mechanisms: 1) Generation of immune complexes (IC) that 
will activate the complement system in order to lyse and opsonize bacteria. Immune 
complexes are composed by a group of antibodies that binds to a pathogen and engage 
components of the complement pathways; 2) Antibodies opsonize pathogens present in the 
extracellular space by binding to Fc receptors on phagocytes; 3) Antibodies recognize and 
neutralize a pathogen or bacterial toxins thus preventing them from attaching to cells 
(inactivation), and 4) antibodies bind pathogen-derived antigens on cell surfaces, such as 
virally encoded proteins, and induce antibody dependent cellular cytotoxicity (ADCC) by 
interacting with Fc receptors on NK cells, CD8 T cells and myeloid cells (6, 22). 
 
3. Mechanisms of central and peripheral tolerance 
Immunological tolerance, i.e., state of unresponsiveness for certain antigens that have been 
previously encountered by the immune system, comprises several mechanisms that are 
important to avoid inadequate immune reactions. For instance, tolerance is essential to 
prevent reactivity against self-components as well as against innocuous air-borne and food 
antigens. A deficient regulation of tolerance may lead to pathogenic autoimmune processes. 
Figure 2 illustrates the various steps of T and B cell tolerance (44, 45, 49). 
 
Figure 2 Mechanisms of central and 
peripheral tolerance of T and B cells. 
Immature T cells (T) enter the thymus and the 
T cell receptor (TCR) undergoes 
rearrangement. T cells with a functional TCR 
will express CD4 and CD8 and those CD4/8 
cells that bind the MHC with low affinity (+) 
are selected. The T cells that bind too strongly 
to the MHC (+++) will be eliminated by 
apoptosis (deletion). Autoreactive T cells also 
die by deletion. Regulatory T cells (Treg) are 
generated in the thymus in order to 
additionally control auto-reactivity. The 
thymus expresses a large amount of antigens 
which contributes to the negative selection of 
T cells (50, 51). In the periphery, T cells that 
escaped central tolerance undergo several 
steps of selection upon presentation of 
antigens by the MHC. Naïve T cells undergo 
anergy (do not become activated) or are deleted in peripheral organs if DCs process and present self-antigens 
through MHC molecules in the absence of co-stimulatory molecules (e.g. CD80 and CD86), i.e. in the absence 
of infection (PAMPs) or inflammation (damage associated molecular patterns: DAMPs). Peripheral tolerance to 
self-reactive T cells is also mediated by Tregs. Auto-reactive B cells are generated because V(D)J 
rearrangements and additional receptor editing are random. B cells of low affinity (+) are positively selected 
whereas those displaying high affinity (+++) to self-antigens are eliminated by deletion or undergo receptor 
editing in the bone marrow in order to express new non-autoreactive BCRs. Autoreactive immature B cells may 
enter a state of anergy if lacking the signals for proper activation. If autoreactive B cells reach peripheral tissues 
they also may enter in a state of anergy or are eliminated in post-germinal centers (22, 44, 45). iDC immature or 
resting DC; mDC, mature DC; +++, high affinity; +, low affinity. 
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4. Autoimmunity and pathologic autoimmunity 
Simply put, autoimmunity arises due to tolerance failure. Albeit autoimmunity is a normal 
occurrence in vertebrate life, the progression to autoimmune disease requires several events 
to take place in parallel and an appropriate microenvironment. Therefore, an autoimmune 
disease is defined as a condition where the constant activation of the adaptive component of 
the immune system, translated by the recurrent presence of autoreactive T cells and/or 
autoantibodies when the infection is no longer present, leads to tissue injury (52). 
 
4.1. Criteria to define autoimmune disease 
Noel Rose and Constantin Bona established several criteria for the definition of autoimmune 
diseases based on Witebsky’s previous claims (53). Table 2 below illustrates the different 
evidence-based autoimmunity definition. 
 
Table 2 Description of the different evidences employed to define the concept of 
autoimmune disease 
Type of evidence Definition 
Direct  
The characteristic lesions of an autoimmune disease are generally replicated through the 
direct transfer of autoantibodies. Between humans: autoantibodies cross the placenta and 
induce disease in the fetus. For example, the transfer of anti-thyroid stimulating hormone 
receptor antibodies causes hyperthyroidism; transfer of anti-Ro antibodies causes 
congenital heart block in the infant. Experimentally, autoimmune disease can be 
reproduced in animals after the transfer of human serum or affinity purified human 
antibodies. For instance, transfer of human Ig from patients with pemphigus into new-born 
mice leads to characteristic skin lesions; administration of anti-acetylcholine receptor 
antibodies to mice causes muscle weakness, characteristic of myasthenia gravis. 
Indirect  
Recognition of causal autoantigen and reproduction of the disease by immunization of 
animals with the identified autoantigen: thyroiditis is induced by the antigen thyroglobulin; 
immunization with acetylcholine receptor causes myasthenia gravis. 
Cell-transfer autoimmune disease: induction of experimental allergic encephalomyelitis by 
CD4
+
 T cells specific for myelin basic protein (MBP); induction of arthritis using collagen 
type II-specific T cells. 
Genetically-induced models: New Zealand black (NZB) mice develop autoimmune 
hemolytic anemia. Autoantibodies purified from NZB mice induce hemolytic anemia in 
healthy mice. Tight-skin (TSK) mice develop scleroderma-like syndrome. Monoclonal 
antibodies from TSK mice and scleroderma patients present similar reactivity against the 
antigen topoisomerase I. 
Additional indirect evidence is given when it is possible to isolate autoantibodies or auto-
reactive T cells from the target organ: isolation of anti-DNA autoantibodies from kidneys 
of patients with SLE; from the thyroid of patients with Grave’s disease it’s possible to 
isolate cytotoxic T cells.  
Circumstantial  
If direct or indirect evidences are lacking an autoimmune disease can be defined 
considering several common indicators. For instance, if the patient has family history, 
simultaneous presence of other autoimmune diseases, high titers of autoantibodies, 
infiltrates in target organ and improvement of certain symptoms after being medicated with 
immunosuppressants.  
 
Approximately 80 different autoimmune diseases are described in the literature. These 
entities span over a broad range of affected organs. On one side of the spectrum the 
autoimmune response targets a specific organ (E.g. Hashimoto's thyroiditis, pernicious 
anemia and Addison’s disease); SLE lies in the opposite side of the spectrum and it is known 
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as a non-organ specific or systemic disease. Rheumatoid arthritis and the idiopathic 
inflammatory myopathies (IIM, such as dermatomyositis, DM and polymyositis, PM) are 
located in the mid part of the spectra because several organs can be affected although not in 
such a wide range as for SLE (6). 
 
4.2. General features of pathologic autoimmunity 
Although autoimmune disease can present different phenotypes, some features are common 
and collectively characterize a pathologic autoimmune event.  
Virtually all autoimmune diseases have a genetic component. The most striking association 
lies on the human leukocyte antigen (HLA) gene family. HLA-DRB1 shared epitope (SE) 
alleles are closely associated with RA (54), and specifically with the presence of 
autoantibodies in sera and synovial fluid (SF) (55, 56). Similarly, HLA-DR phenotype has 
been associated with a subset of IIM patients having anti-histidyl transfer RNA synthetase 
(HisRS) antibodies (aJo1) (57, 58). HLA has also been associated with other autoimmune 
diseases. HLA-DRB1*03:01 was found to correlate with SLE (59), type I diabetes (60) and 
scleroderma (61). 
 
Environmental factors are also considered a major contributing risk factor for autoimmune 
diseases. Smoking, chemicals, UV light, drugs and infections are recognized environmental 
triggers that when exposed to susceptible organs (e.g. mucosal sites such as the lung) may 
initiate an immune response. Smoking, for example, has been associated with anti-
citrullinated protein/peptide antibodies (ACPA)-positive RA as well as with aJo1-positive 
IIM. Moreover, evidence shows a correlation between HLA-DRB1 alleles and smoking in 
both these seropositive disease populations (57, 62). Viral and microbial infections have also 
been debated as an etiological agent, although no solid proofs have been provided yet. Some 
concrete examples of infections seemingly associated with RA are those induced by 
Porphyromonas gingivalis (PG) and Epstein-Barr virus. Patients with periodontitis and 
infected with PG have a higher likelihood of developing RA, whereas seropositive (ACPA 
and rheumatoid factor, RF) RA patients are more likely to have moderate to severe 
periodontitis (4, 63, 64). Coxsackie viruses were suggested to be involved in the initiation of 
IIM (more specifically PM and DM) (65-67). A flagrant example of an autoimmune 
condition induced by exposure to a drug is the statin-induced necrotizing myopathy. These 
patients develop severe muscle weakness and autoantibodies against 3-hydroxy-3-
methylglutaryl-coenzyme A reductase (HMGCR), the target of statins, after medication with 
statins. However, it is still under debate whether anti-HMGCR antibodies are a true 
autoimmune response or just an epiphenomenon (68, 69).  
The fact that there is a sex bias in a large percentage of autoimmune diseases raises the 
question whether hormones play a role in the aetiology of such conditions (44). 
 
4.3 Autoantigens and autoantibodies 
When the immunological tolerance to self-antigens fails an autoimmune process initiates. 
One of first manifestations is the occurrence of autoantibodies that arise as an immune 
response towards those self-antigens (70, 71). Autoantibodies target different types of 
molecules namely, proteins, nucleic acids and lipids that can be located in the nucleus or 
cytoplasm, membrane surface or in the extracellular environment. In some autoimmune 
9 
 
diseases the affected tissues or organs express unique antigens that become the specific target 
of the immune response (e.g. MBP in multiple sclerosis). In other cases, autoantibodies are 
raised against ubiquitously expressed proteins (topoisomerase 1 in scleroderma, HisRS in IIM 
or histone 4 in RA are some examples). Some currently known autoantibodies are listed in 
Table 3. The reasons why certain tissues (lung, muscle, joint) are targets of an autoimmune 
attack, why certain molecules become autoantigenic and whether autoantibodies intervene in 
the initiation and development of an autoimmune disease are active areas of research (72, 73). 
 
Table 3 Autoantibodies used as diagnostic and prognostic biomarkers (Table adapted from 
‘The autoimmune disease fifth edition’, chapter 77 by Marvin J. Fritzler) (44) 
Autoantibody Antigen Disease 
ACPA Citrullinated proteins/peptides RA 
RF Fc region of IgG RA 
Anti-aaRS Aminoacyl-transfer RNA synthetases Myositis; ASS 
Anti-DNA DNA packed around histones SLE 
Anti-Ro52 (SSA) Tripartite Motif Containing 21 SLE; Other SAD 
Anti-Ro60 (SSA) 
Ribonucleoprotein from TROVE (Telomerase, Ro and Vault) 
domain family member 2 
SLE, SjS 
Anti-La (SSB) 
3' poly(U) terminus of nascent RNA polymerase III transcripts 
48 kDa binding protein 
SLE, SjS 
Anti-Scl-70 Type I DNA Topoisomerase SSc 
Anti-CENPB Centromere protein B SSc 
Anti-Sm Complex of small nuclear ribonucleoproteins SLE 
Anti-Pm-Scl Exosome complex SSc 
ANCA Myeloperoxidase (p-ANCA) and proteinase 3 (c-ANCA) Vasculitis 
ACA Cardiolipin APS; SLE 
Anti-Lupus 
anticoagulant 
Phospholipids APS; SLE 
Anti-tTG Tissue transglutaminase CD 
Anti-TPO Thyroid peroxidase HT 
Anti-AChR Acetylcholine receptor MG 
Anti-desmoglein Desmoglein (cadherin-like transmembrane glycoprotein) PV 
AMA Mitochondria PBC 
 
RA, rheumatoid arthritis; ASS, anti-synthetase syndrome; SLE, systemic lupus erythematosus; SAD, systemic autoimmune 
diseases; SjS, Sjögren’s Syndrome; SSc, Systemic sclerosis or scleroderma; APS, anti-phospholipid syndrome; PA, 
pernicious anemia; CD, celiac disease; HT; Hashimoto’s thyroiditis; MG, myasthenia gravis; PV, pemphigus vulgaris; PBC, 
primary biliary cirrhosis. 
 
4.3.1 Autoantibody generation 
Defects in the tolerance checkpoints at a central level are known to occur in autoimmune 
diseases (74, 75). However, it appears that somatic hypermutation in the GCs in secondary 
lymphoid tissue may also be important for the generation of autoreactive B cells (Figure 1). 
Memory B cell-derived autoantibodies in systemic autoimmune diseases such as SLE and RA 
are usually hypermutated and class-switched, which shows their participation in GC 
processes (74, 76-81). Autoantibody diversification and production can also occur in ectopic 
structures in non-lymphoid target organs such as the lung and synovial tissue in RA and 
kidney in SLE (72, 82-84). 
 
One mechanism by which loss of tolerance takes place is when self-proteins undergo 
modifications which lead to generation of new epitopes that are not expressed in the thymus, 
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and thus have not been engaged in negative selection and tolerization. After the protein 
synthesis, the amino acids undergo covalent alterations designated post-translational 
modifications (PTM). In a normal setting, PTM are important regulators of the function of a 
protein namely by affecting the activity, interactions, subcellular localization, stability and 
proteolytic degradation. Among hundreds described, phosphorylation, citrullination, 
ubiquitination, glycosylation, proteolysis and acetylation are some common examples of 
PTMs (85). These processes affect the primary, secondary and tertiary structure of proteins 
and in certain contexts such as inflammation and cell death (apoptosis, necrosis and 
lymphocyte granule pathway) may affect antigen selection and processing and thereby 
installing an autoimmune process (86-88).  
 
During apoptosis (for example in SLE) autoantigens were found to cluster in apoptotic blebs 
on the cell surface, promoting the release of intracellular antigenic targets such as DNA and 
ribonucleoproteins (89). Normally, these apoptotic blebs are taken up by phagocytes with no 
major consequences. However, in a context of defective apoptotic clearance as observed in 
autoimmune conditions, intracellular antigens accumulate in the extracellular milieu and may 
drive autoantibody generation. The process of programed cell death stimulates the formation 
of different PTMs as is the case of citrullination which is the PTM known to have the 
strongest association with RA. This PTM will be described in more detail in the section 5.4.1 
of the introduction. 
 
In the case of myositis the lymphocyte granule pathway seems to be the major form of cell 
death. Several myositis related autoantigens were shown to be susceptible to cleavage by 
proteases contained in cytotoxic lymphocyte granules. Upon cleavage by, for example, the 
serine protease Granzyme B (GrB), novel fragments are formed which renders the antigen 
immunogenic properties that may lead to autoantibody generation (90-92). 
 
An alternative type of cell death occurs when neutrophils release chromatin webs (neutrophil 
extracellular traps, NETs) which trap bacteria – NETosis. Besides microbial peptides, NETs 
were demonstrated to expose pro-inflammatory mediators (e.g. IL-17), and post-translational 
modified autoantigens such as citrullinated, methylated and acetylated histones (in RA and 
SLE, respectively). Moreover, NETosis was shown to be enhanced in RA and to associate 
with the presence of ACPA and pro-inflammatory molecules. These findings suggested that 
defective NETosis in RA may contribute to the autoimmune process and disease 
pathogenesis (87, 93-97). 
 
The importance of autoantigens as disease drivers can be discussed from another viewpoint. 
The main target organ of an autoimmune response may not always be the main source of the 
autoantigen, initially. A compelling example is the enzyme HisRS and the muscle in IIM. 
HisRS is one of the most common autoantigens in IIM (described in detail in section 6.2.1 of 
the introduction) whereby the muscle is the major target organ. Casciola-Rosen and co-
workers (98) clearly showed that HisRS is highly expressed in regenerating muscle fibers in 
IIM whereas only very low levels are detected in healthy differentiated muscle fibers. The 
fact that HisRS is overexpressed in this particular condition suggests that it is the regenerating 
muscle fiber rather than the healthy muscle fiber that is the target of an autoimmune response. 
In addition, HisRS was suggested to act as a tissue-chemoattractant since it was shown to 
activate immature DC and naïve lymphocytes via C-C chemokine receptor type 5 (CCR5) 
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(99). These observations provide support for the crucial role of autoantigens as disease 
drivers in a pathogenic autoimmune situation (90, 92, 100). 
 
4.3.2 Autoantibodies in diagnosis and pathogenic mechanisms 
Sensitivity, specificity, positive or negative predictive values and receiver operating 
characteristic (ROC) curves are important concepts in the analysis of diagnostic tests. The 
term sensitivity translates the proportion of patients that test positive due to the fact that they 
have the disease thus, the patient is correctly identified by the test. The probability an 
individual has of presenting the disease because that subject tested positive, is denoted as the 
positive predictive value. The term specificity is the proportion of individuals that test 
negative for the disease because they do not have the disease. The probability an individual 
has of not having the disease because the test was negative, translates the negative predictive 
value. The ROC curves give a correlation between the sensitivity and specificity (101, 102). 
 
Disease definition and classification. Autoantibodies are good disease markers and are 
commonly used for diagnostic purposes. Laboratory techniques such as enzyme-linked 
immunosorbent assay (ELISA), immunofluorescence or immunoprecipitation are regularly 
used to detect autoantibodies in patient serum. Anti-mitochondrial antibodies (AMA) are 
included in the diagnostic criteria of primary biliary cirrhosis. Around 90-95% of patients 
have AMA (103). The presence of anti-parietal cells or anti-intrinsic factor (important for 
Vitamin B12 absorption) autoantibodies together with atrophic gastritis and vitamin B12 
levels translates the diagnosis of autoimmune gastritis (also termed pernicious anemia) (104, 
105). 
 
Disease activity and prediction. The presence of autoantibodies may give insights on 
disease activity, severity and prognosis and the severity of a chronic inflammation is often 
reflected by the intensity of the immune response. As autoantibodies are a consequence of the 
pro-immune setting, they can in some cases be used as indicators of disease activity e.g. anti-
DNA and anti-Jo1 antibodies (predicting rate of progression). In many autoimmune diseases 
autoantibodies are present several years before clinical onset. In type 1 diabetes and 
thyroiditis, which are organ-specific conditions, circulating autoantibodies have been detected 
before the destruction of hormone-secreting cells. The autoantibody titers in these cases may 
reflect disease severity (106, 107). The occurrence of autoantibodies is sometimes associated 
with the development of a more aggressive disease, as observed for ACPA+ RA patients 
having more severe erosions and bone loss compared to ACPA- RA. In addition, ACPA may 
also be detected long before the first clinical symptoms, up to 10 years, and affinity 
maturation, isotype switching and increased epitope spreading take place close to diagnosis 
(further details in section 5.4.1.1 of the introduction). The ability to predict a disease, 
especially in those individuals with a long pre-clinical stage, is essential for prevention. These 
subjects may avoid certain environmental risk factors, known to have a direct correlation with 
that specific autoimmune disease. Individuals with pre-existing autoimmunity may be treated 
during the pre-clinical stage (105, 108). 
 
In addition, autoantibodies may be useful molecular tools since they can be employed to 
isolate the cognate molecules and therefore study the molecular mechanisms behind the 
disease. The role of small nuclear ribonucleoproteins (snRNP) in splicing-messenger RNA 
has been possible to study due to the use of anti-snRNP antibodies to immunoprecipitate 
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snRNP (109). Likewise, anti-centromere autoantibodies, characteristic of scleroderma 
patients, were employed to elucidate the structure and function of kinetochore (protein 
involved in chromosome condensation and cell division) (110). 
 
Although some autoantibodies are harmless (e.g. natural autoantibodies), others have proven 
to be pathogenic. The affinity/avidity, epitope specificity, class/sub-class and glycosylation 
pattern of an autoantibody influence its pathogenic effects. Several mechanisms defined 
above for antibodies also apply in this particular situation (111): (1) Opsonization and 
phagocytosis- Autoantibodies bound to target cells activate mononuclear phagocyte cells 
through Fc receptor interaction. Target cells are engulfed and destroyed (example, anti-
erythrocyte antibodies in SLE and autoimmune hemolytic anemia) (112); (2) Complement 
system – Autoantibodies induce the membrane attack complex mainly via activation of the 
classical pathway. The complex creates a transmembrane gate and the passage of water and 
electrolytes disturbs the osmotic balance and consequently the cells lyse (autoimmune 
hemolytic anemia) (113). A deficiency in the complement system (e.g. C1q) is associated 
with susceptibility to develop SLE. This may be due to an impaired capacity of IC and 
apoptotic material clearance. Complement activation was also shown to be associated with 
inflammation and organ damage in SLE (e.g. C3a and C5a act as chemoattractant agents for 
leucocytes; renal deposition of C5b-9 releases inflammatory mediators) (114-117); (3) Cell 
engagement or ADCC - Autoantibodies bound to a target cell are recognized by Fc receptors 
on NK and CD8
+
T cells that carry proteases-containing granules. In turn, these cytotoxic 
enzymes induce apoptosis of antibody-coated cells (anti-TPO autoantibodies and 
autoimmune thyroiditis) (118); (4) Immune complex - IC deposition is a characteristic 
feature of several autoimmune diseases. Through binding to Fc receptors or complement 
system, autoantibody-containing ICs promote local inflammation and consequently tissue 
damage (e.g. joints in RA and kidneys in SLE). Mechanistically, cell destruction takes place 
as described above. IC can also engage Fc receptors in NK and CD8
+ 
T cells (6, 111). 
 
5. Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic inflammatory disorder with an overall prevalence of 
0.5 to 1% in western countries and an incidence of 2-50/100 000/per year. RA has a regional 
distribution, being more predominant in areas such as North America and North Europe and 
similarly to other autoimmune diseases women are more often affected than men. In RA the 
joints are targets of major damage and persistent inflammation in the synovium causes pain, 
joint swelling, and cartilage and bone destruction, ultimately leading to severe disability. 
Extra-articular involvement is often present, i.e. lung, heart, muscle, blood vessels, skin and 
eyes, representative of a systemic condition. An autoimmune component adds to the spectrum 
of RA as several autoantibodies are present in a large majority of the patients (44, 119-121). 
However, the immune specificities have not been clarified in detail. Furthermore, whether the 
antibodies are pathogenic or an epiphenomenon will be further discussed below. 
 
5.1.  Classification criteria 
With the aim of distinguishing RA from other arthritides (characterized by inflammation in 
the joints or in other components of the musculoskeletal system) and considering the 
heterogenic nature of RA, two classification criteria are currently utilized: 1987 American 
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College of Rheumatology (ACR) (122), and 2010 ACR-European League Against 
Rheumatism (EULAR) (123, 124) criteria. The description of each set of criteria is listed in 
Table 4. 
 
Table 4a Classification criteria for RA – The 1987 ACR criteria 
Criterion Manifestations Score 
1. Morning stiffness In and around the joints for ≥ one hour 1 
2. Arthritis in three or 
more joints 
Simultaneous soft tissue swelling or fluid in three out of 14 joint 
areas: right or left proximal interphalangeal (PIP), 
metacarpophalangeal (MCP), wrist, elbow, knee, ankle, and 
metatarsophalangeal joints 
1 
3. Arthritis of hand joints One or more swollen areas in a wrist, PIP or MCP joint. 1 
4. Symmetric arthritis Simultaneous bilateral involvement of the same joint areas as 
defined in 2 
1 
5. Rheumatoid nodules Subcutaneous nodules above bony prominences, or extensor 
surfaces, or in juxta-articular regions  
1 
6. Serology Presence of rheumatoid factor in serum 1 
7. Radiographic changes Typical for RA on posteroanterior hand and wrist radiographs. 
These include erosions or clear bone decalcification in or adjacent 
to the involved joints 
1 
Diagnosis: Four of the seven criteria should be fulfilled and criterion one to four should have been present 
for at least six weeks. 
 
Table 4b Classification criteria for RA – The 2010 ACR/EULAR criteria 
Criterion Manifestations Score 
A. Joint involvement 
1. One large joint (shoulders, elbows, hips, knees, and ankles) 
2. Two to ten large joints 
3. One to three small* joints with or without large joint 
involvement (
*
MTP and PIP joints, second through fifth 
MTP joints, thumb interphalangeal joints, and wrists)
 
4. Four to ten small joints (with or without large joint 
involvement) 
5. More than ten joints (at least one small joint) 
0 
1 
2 
 
 
3 
 
5 
B. Serology 
1. Negative RF and negative ACPA 
2. Low-positive RF or low-positive ACPA 
3. High-positive RF or high-positive ACPA 
0 
2 
3 
C. Acute-phase reactants 
1. Normal C-reactive protein (CRP) and normal erythrocyte 
sedimentation rate (ESR) 
2. Abnormal CRP or abnormal ESR 
0 
 
1 
D. Duration of symptoms 
1. < six weeks 
2. ≥ six weeks 
0 
1 
Diagnosis: Six or more of the maximum ten points. This criteria aims at early diagnosis. 
 
5.2. Etiology 
The reason why and how RA initiates and develops is still enigmatic. However, compelling 
evidence suggests the interaction between genetic and environmental factors as a crucial 
trigger. Data from twin studies provide a good opportunity to investigate the impact that both 
genes and environment display on a disease. RA prevalence in twins was shown to be 
increased by ~15% in comparison to the general population (119, 125). More recently, 
MacGreggor and co-workers (126) analysed two European twin populations and reported a 
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higher heritability contribution of RA in the range of 60%. Several genes have been 
associated with RA. The most striking associations lie on HLA alleles, though non-HLA 
genes have also been reported, such as peptidyl arginine deaminase 4 (PAD4), protein 
tyrosine phosphatase non-receptor type 22 (PTPN22), Tumor Necrosis Factor α-Induced 
Protein 3, signal transducer and activator of transcription 4, chemokine (C-C motif) receptor 
6 and interferon regulatory factor 5 (54, 108, 127). Interestingly, HLA-DR variants associated 
to RA have a common sequence of amino acids in their antigen-binding grove, termed shared 
epitope (SE) which may indicate that a selection of antigens is presented to T cells and 
consequently provides evidence for the role of adaptive immunity in the development of RA 
(128). Smoking is a well-established environmental risk factor for RA. It correlates with 
ACPA positivity, disease activity and extra-articular manifestations (129-132). A striking 
association between SE genotype and smoking has been demonstrated for the ACPA+ 
population of RA, and it will be further discussed in the following sections. 
 
5.3. Pathological features 
The major target organ in patients with RA is the joint. The clinical presentation of RA varies 
among patients, with some individuals experiencing a more aggressive disease (serious 
cartilage and bone loss), while others do not present erosions. Small and medium size joints 
are usually symmetrically affected. The systemic manifestations affect the patients in a 
heterogeneous way. The most common extra-articular sign is the presence of rheumatoid 
nodules in the juxta-articular region and in the lungs. Rheumatoid arthritis is associated with 
an increased risk for both cancer (lymphomas) and co-morbidities (cardiovascular disease 
and interstitial lung disease, ILD). Arthritic synovial joints display typical pathologic 
features, represented in Figure 3 (120, 121, 133, 134). 
 
Figure 3 Illustration of a normal (a) and 
arthritic (b) synovial joint. (a) The synovial 
joints (intended to facilitate movement between 
adjacent bones) are surrounded by a capsule. The 
adjacent bones are covered by a protective thin 
layer of cartilage and the synovial membrane. The 
synovium, or synovial membrane, is composed of 
synoviocytes (macrophage and fibroblast derived), 
blood and lymph vessels and a few mononuclear 
cells. The synovial cavity is filled with synovial 
fluid (SF) containing lubricants and nutrients. The 
initial phase of clinical RA (b) is characterized by 
synovitis (inflammation of the synovium), 
translated by an increased number of adhesion 
molecules and consequent influx and activation of 
T and B cells, NK cells, granulocytes, mast cells, DC, plasma cells and macrophages into the synovial membrane 
as well as the SF. New blood vessels form and the cells from the lining layer proliferate leading to thickening of 
the synovium. The cartilage is degraded and the osteoclasts promote bone erosion (’pannus’). The SF contains 
high amounts of inflammatory cells that produce prostaglandins and oxygen-reactive species, thus contributing 
to the progress of inflammation and volume expansion. Fibrin deposits are found in the joint and further 
contribute to the ongoing inflammation. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Drug 
Discovery Smolen JS & Steiner G, Vol. 2(6), p.47 copyright 2003 http://www.nature.com/nrd/journal/v2/n6/full/nrd1109.html 
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5.4.  Seropositive RA  
The presence of circulating autoantibodies is a common manifestation of autoimmune 
diseases. A large subset of RA patients produces autoantibodies that target different cellular 
components. The antibodies are helpful in the diagnosis of RA to distinguish patients with 
RA from other chronic arthritis. However, if the antibodies have a role in the pathogenesis is 
still an enigma. To learn more about the role of autoantibodies in the pathogenesis of RA 
more detailed information is needed on the different reactivities that compose the 
autoantibodies pool (Paper I) and other characteristic features such as affinity maturation and 
glycosylation patterns (discussed below), which may dictate their effector functions (Paper 
II). 
 
The rheumatoid factor (RF) was for a long time considered the only serological marker 
included in the classification of RA. The RF (mainly IgM but to a less extent also IgG and 
IgA) recognizes the Fc region of IgG and is present in up to ~80% of RA patients. Several 
studies have shown an association between RF and severe, destructive RA. However, RF is 
not specific for RA as it has been reported in healthy individuals, in patients infected with 
viruses and in other chronic inflammatory disorders (135-137). 
 
Antibodies directed towards carbamylated proteins (anti-carP antibodies) were recently 
found in RA patients. These autoantibodies were detected in both the CCP+ and the CCP- 
RA populations (30% and 16%, respectively) and found predictive of a severe disease course 
(138). Recent studies show that the presence of this subset of antibodies predicts development 
of RA in patients with arthralgia. Similarly to RF and anti-cyclic citrullinated peptides (CCP) 
antibodies, anti-CarP antibodies are also detected before onset of RA. Figure 4 illustrates 
citrullination and homocitrullination, two of the major PTMs in RA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Representation of citrullination and homocitrullination. The conversion of arginine to citrulline by 
means of a peptidylarginine deiminase (Ca
2+
-dependent enzyme, PAD) is targeted by ACPA (or anti-CCP 
antibodies), upper panel. Homocitrulline is produced from lysine through a chemical reaction (termed 
carbamylation) that requires cyanate. The cognate autoantibodies are termed anti-carP antibodies, lower panel. 
 
Interestingly, antibodies directed against PAD4 (anti-PAD4 antibodies) were found to 1) 
occur in 36-42% of RA patients, 2) precede RA clinical onset for several years (18.1% of 
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individuals) and 3) to be associated both with erosive arthritis and with ILD. A positive 
association between the presence of these antibodies and anti-CCP antibodies was also found. 
Notably, anti-PAD4 antibodies recognize an epitope located in the N-terminus of the PAD 
enzymes that contains three RA-associated polymorphisms. In addition, anti-PAD4 
antibodies were shown to cross-react with anti-PAD3 antibodies and to alter the enzyme 
requirement for calcium. This finding demonstrates the autoantibody’s ability to institute a 
feed-forward loop that may be a critical step in the progression of bone erosion (139-144). 
 
5.4.1. The case for citrullinated proteins and ACPA 
Anti-citrullinated protein/peptide antibodies (ACPA) are a subset of autoantibodies that are 
present in up to 70% of RA patients. ACPA occur as a response to proteins in which arginine 
residues are converted to citrulline residues, a PTM termed citrullination or deamination 
(Figure 4) (145). The reduction in the net charge of the amino acid residues, as they become 
citrullinated, renders the proteins immunogenic features, leading to tolerance breach to 
previous known self-proteins. 
 
The enzymatic reaction of protein citrullination is an important physiological process 
mediated by a class of calcium-dependent enzymes termed PADs, of which five members are 
described. The tissue distribution and substrate specificities differ among the five PAD 
members (PAD1-4 and PAD6) (145, 146). For instance, PAD1 has a fundamental role in 
keratinocyte differentiation, and therefore has a high level of expression in the epidermis; 
PAD3 is involved in hair follicle development; PAD2 is expressed in the brain (important 
during development of central nervous system) and in the skeletal muscle. Hematopoietic 
cells express both PAD2 and PAD4. PADs have been also demonstrated to be involved in the 
regulation of the immune system, e.g. in the formation of NETs and modulation of 
chemokine activity (147, 148). 
 
An abnormal degree of protein citrullination characterizes RA. In the rheumatic joint several 
proteins were shown to be citrullinated (fibrinogen, vimentin, α-enolase, type II collagen 
(CII), histone 4, immunoglobulin binding protein and annexin). In addition, circulating 
antibodies targeting those citrullinated proteins have being reported (93, 149-159). Anti-
citrullinated type II collagen, fibrinogen, α-enolase and vimentin antibodies composed the 
four best described ACPA fine-specificities and they will be further discussed in the section 
results and discussion (Paper I). PAD2 and 4 are expressed in the synovial joint (tissue and 
synovial fluid, both intra and extracellularly) (146, 151, 153, 160, 161). The differential 
distribution of PAD enzymes and substrate specificity may produce various citrullinated 
peptides that could be recognized by autoreactive T cells (160, 162). The generation of 
intracellular citrullinated autoantigens in RA has been suggested to take place extracellularly 
after cell death, because PADs need high concentration of calcium to catalyze the reaction. 
The intracellular concentration of calcium is too low for PAD requirements (153). More 
recently, protein citrullination in RA was suggested to be “cell-associated” and to occur in a 
high number of proteins, to which the authors coined the term “cellular hypercitrullination”. 
Perforin and membrane attack complex (MAC) pathways were demonstrated to activate 
PADs and to induce hypercitrullination in synovial fluid cells (e.g. neutrophils). Apoptosis, 
NETosis, and autophagy/necroptosis as well as activation signals such as cytokines were not 
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able to induce such a great rate of citrullination further suggesting the importance of immune-
mediated pore forming pathways in this process (163). 
 
Hypercitrullination of proteins has been shown not only in RA but also in multiple sclerosis, 
Alzheimer’s disease and to some extent myositis, which demonstrates that abnormal protein 
citrullination is a common phenomenon in chronic inflammatory conditions (156, 164, 165). 
Notably, the occurrence of autoantibodies that target citrullinated proteins, ACPA, has been 
shown to be specific, although not entirely exclusive, for RA as they have also been reported 
in other rheumatic conditions, for instance: 5 to 14% of patients with Primary Sjögren’s 
syndrome (166-168), up to 27% and 24% of patients with myositis (167, 169) and 
scleroderma (170, 171), respectively, and 14% of patients with ankylosing spondylitis (167). 
A French case-control retrospective study identified 17 ASS patients that contain ACPA. All 
ACPA+ ASS patients presented arthritis in comparison to 41% of ACPA- ASS (172). 
 
In the clinical setting, ACPA are routinely measured using a commercial ELISA based on a 
library of cyclic citrullinated peptides (“second generation” anti-CCP ELISA) (173, 174). 
Although a good diagnostic tool, anti-CCP antibodies are considered a surrogate marker for 
RA since CCP do not translate a ‘real’ human protein sequence. Studies in the past years 
(including paper I of this thesis) have been elucidating the nature of these autoantibodies, 
their reactivities and whether their autoantigens represent rheumatoid tissue targets present in 
vivo or not (56, 175-179). Knowledge on the “real” ACPA targets may lead to the design of 
more tailored therapies (e.g. oral tolerance) and it may provide clues for the etiopathology of 
RA. 
 
A support for a role of autoantibodies in pathogenesis is that they are present before disease 
symptoms. Indeed, circulating ACPAs have been detected several years before RA onset, 
with titers and number of reactivities rising closer to the time of diagnosis (70, 176, 178, 180-
184). The presence of these antibodies classifies a subset of RA characterized by worse 
prognosis and poor outcome (185-190). In addition, the presence of ACPA predicts the 
development of RA in 40 to 70% of individuals with arthralgia and helps to identify patients 
at risk. The sustained presence of different ACPA isotypes translates an ongoing activation of 
ACPA producing-B cells and the enrichment of ACPA in the joints is suggestive of a locally 
driven immune response (191-193). Additional evidences suggest ACPA to mediate a major 
role in the pathogenesis and development of RA (Figure 5). Although the joint is the major 
target in RA, the starting point of immune reaction is still not clear. A number of recent 
studies provide compelling evidence for the role of lungs as the initiating organ. But the 
question then remains as to why the inflammation attacks the joints. Figure 5 illustrates one 
current hypothesis for how ACPA+ RA is initiated, how it evolves and the major underlying 
molecular mechanisms (62, 70, 83, 108, 157, 177, 180, 181, 183, 184, 192, 194-208). 
 
5.4.1.1. ACPA features 
In vivo antibody responses undergo isotype switching and affinity maturation. These are 
important processes because they regulate the effector function of an antibody and 
consequently influence the immune response. 
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Figure 5 Hypothesis for the initiation and development of CCP/ACPA+RA. RA is a multifactorial disease whereby an interaction between a certain genetic background and different 
environmental risk factors may trigger an initial extra-articular (e.g. lung) immune response that ultimately reaches the synovial joints. (1) Circulating ACPAs (as well as other 
autoantibodies) are detected before signs of inflammation in the synovial joint; ACPA+ individuals who are smokers and carry the HLA-DRB1 SE genes display an increased risk of 
developing RA in comparison to the ACPA-RA population. Smoking leads to an increased number of citrullinated proteins in the lungs. Apoptotic cells leak PAD enzymes into the 
extracellular environment and additional proteins become citrullinated (as the concentration of calcium is higher extracellularly). An enrichment of ACPA as well as presence of ectopic 
lymphoid structures (in untreated ACPA+RA and ACPA+ individuals without joint involvement) has been reported in the lungs. Citrullinated proteins are processed and presented by DC 
to T cells through HLA SE molecules, which leads to activation of B cells and production of autoantibodies. (2) Pre-clinical RA is characterized by sub-clinical systemic inflammation 
visualized by magnetic resonance imaging (MRI) but no clinical signs of synovitis. In line, MRI of non-RA ACPA+ individuals show no inflammation in the joints. However, bone loss 
has been reported in ACPA+ subjects before RA diagnosis, suggesting that bone may be affected prior to the synovial membrane. Close to the clinical onset ACPA undergo epitope 
spreading and a simultaneous rise in circulating pro-inflammatory cytokines and chemokines takes place. (3) A second hit (trauma or infection) may be necessary for the autoimmune 
response to reach the synovial joints. ACPA are enriched locally in the SF (with higher prevalence of certain reactivities such as α-enolase), bind to local citrullinated proteins and 
mediate effector functions that drive and perpetuate synovial inflammation and bone loss: activation of complement (via both the classical and alternative pathways); generation of TNF-α 
by macrophages; induction of osteoclastogenesis and bone loss; activation of synovial mast cells through TLR engagement; stimulation of macrophages through engagement of both 
TLR-4 and FcR. ACPAs were recently shown to associate with NETs, which are an additional source of citrullinated proteins. Perforin and membrane attack complex-medicated 
hypercitrullination occurs in SF cells (“cellular hypercitrullination”); Citrulline reactive-B cells are also abundant in the SF and may function as APC. The presence of common 
citrullinated proteins in the lung and synovial joint adds to the lung/joint axis hypothesis of RA pathogenesis. Periodontitis may also be an additional driver for the pathogenesis of RA. 
Antibodies targeting the bacteria Porphyromonas Gingivalis (PG) have been detected in RA patients and in individuals at risk. An association between periodontitis and RA has also been 
reported. Furthermore, PG express its own PAD raising the possibility that bacterial PAD may citrullinate proteins other than the ones with bacterial origin. SE, shared epitope; DC, 
dendritic cell; CP, citrullinated proteins; IC, immunecomplexes; PIC, pro-inflammatory cytokines; SFib, synovial fibroblasts; NETs, nuclear extracellular traps. CHyp, Cellular hypercitrullination.
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ACPA IgG, IgM and IgA isotypes have all been documented in RA patients, and they 
appear to have distinct distribution in comparison to healthy relatives (19% of the unnafected 
relatives of those RA patients we ACPA+) (209). Within ACPA IgG, IgG1 is the most 
common form and is present both in circulation and in the SF of RA patients. Notably, ACPA 
IgG was detected in BAL from early RA and sputum from individuals at risk of developing 
RA (Figure 3) (83, 201, 209). Interestingly, the expansion of ACPA isotype distribution 
occurs before the onset of RA, and similarly to what is observed for epitope spreading, it does 
not magnify after the diagnosis (181, 191). Similarly to ACPA IgG, also circulating IgA 
isotype was found before RA diagnosis. In this study, both the isotypes were found to predict 
the development of RA (210). In fact, the number of isotypes was found to correlate with RA 
development and progression and further, the isotype profile at disease onset predicted 
radiographic damage (211). Nonetheless, ACPA IgA was recently found in saliva of RA 
patients that develop less severe joint erosion, which is suggestive of a mucosal ACPA IgA-
mediated anti-inflammatory function (212). 
 
The affinity of antibodies develops overtime. In a primary immune response the affinity is 
generally low, increasing throughout the course of the response. This is called affinity 
maturation and the process is enhanced by lower levels of antigen. As mentioned above, 
avidity provides a more accurate assessment of the binding strength between an antibody and 
its cognate antigen. ACPAs were shown to have low avidity in comparison to antibodies 
against recall antigens (tetanus toxoid and diptheria toxoid) and to undergo affinity 
maturation prior to onset of arthritis, without further maturation after diagnosis. In addition, 
patients with ACPA displaying lower avidity presented more joint destruction than those with 
higher avidity. These findings may suggest that low-affinity ACPA are more effective at 
binding citrullinated antigens. In line, the constant supply of citrullinated antigens may lead 
to a continuous production of ACPA thus, perpetuating the pathogenic immune response 
(213-215). The joint erosions associated with ACPA+ disease may be due to the effector 
functions low avidity ACPA execute, e.g. more effective at activating the complement system 
(213). In paper IV we explore the possible existence of high affinity ACPA subtypes among 
the total RA ACPA pool. 
 
The glycosylation patterns of an antibody have a major influence on its functionality since 
they affect the physiochemical properties of the antibody by altering its structure and 
conformation. These alterations have implications, for example, in the bond between IgGs 
and Fc receptors (FcR) or complement components as well as in antibody dependent cell-
mediated toxicity. Interference with antigen recognition due to glycosylation of the antibody 
has also been reported. Antibodies may regulate the immune response in a pro- or anti-
inflammatory way depending on the glycosylation features. Antibodies containing sialic acid 
residues in the constant fragment display a more anti-inflammatory profile (216). 
In serum, the Fc part of ACPA was shown to be more agalactosylated and to lack sialic acid 
residues, in comparison to the non-ACPA IgG1-Fc part (217, 218). In addition, ACPA 
existing in SF differs from ACPA circulating in serum and, furthermore, ACPA-glycans were 
also shown to vary among the four isotypes (IgG1-4) (217, 219). ACPA Fab-peptide 
sequences seem to differ from non-ACPA RA IgG. Very recently, Rombout et al (220) 
showed that ACPA Fc glycans exhibit pro-inflammatory properties already before the disease 
onset. Furthermore, hyperglycosylation of ACPA variable domains was reported, whereas no 
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such alterations were registered for other autoantibodies or antibodies against recall-antigens 
(221). Together, these findings provide evidences for the importance ACPA glycosylation 
patterns have in mediating pro-inflammatory responses and thus, ACPA pathogenicity. 
 
5.5. Pain in RA 
Pain is one of the most disabling features of RA. A large majority of patients consider pain 
treatment the factor that needs better improvement in the disease management (222). 
Although different treatments are given to RA patients, non-steroidal anti-inflammatory drugs 
(NSAIDS), non-biological disease-modifying anti-rheumatic drugs (DMARDs) or biologics, 
the pain often persists after decrease of joint inflammation, improvement of disease activity 
or even when patients are in remission. Additionally, arthralgia (joint pain), in many cases, 
develops before synovitis and is predictive of development of RA (223-225). 
 
Pain results from the perception and recognition of an injured organ that has been exposed to 
noxious thermal, mechanical or chemical stimuli (nociception). The nerve cells that primarily 
sense and respond to these stimuli by sending signals to the spinal cord and brain are called 
nociceptors. Anatomically, the cell bodies of nociceptors locate both in the dorsal root 
ganglia (responsible for the body area) and in the trigeminal ganglia (responsible for the 
face). In addition, nociceptors have a peripheral branch that innervates the organs, and a 
central branch that connects with the spinal cord. Dorsal root ganglia (DRG) and trigeminal 
ganglia (TG) are groups of neurons responsible for conveying sensory information from the 
periphery to the central nervous system (226-228). 
 
Nociceptors are high-threshold fibers that can broadly be divided into categories depending 
on axonal size and thus conduction speed. Another way to classify nerves is according to 
their response to environmental stimuli: mechanical, thermal or chemical. The nociceptors 
that sense and transmit acute and fast pain (retraction behaviour) contain myelinated afferent 
A delta fibers (A) of medium diameter (type I). These A fibers can be sub-classified in two 
additional types: one responds to mechanical and chemical stimuli while having a high 
threshold for heat, and the other type senses thermal stimuli while having a higher threshold 
for mechanical stimulation. Additionally, type I nociceptors comprise A fibers of a larger 
diameter that are responsible for conducting mechanical stimulation. Type II nociceptors 
comprise unmyelinated fibers of small diameter (C fibers) that perceive slow pain. Also here 
fibers respond to both mechanical and thermal stimuli. In an inflammatory context these 
fibers lower their thresholds and become increasingly sensitized to otherwise normal stimuli 
(226-228). 
 
 
Figure 6 Pain follows a route that starts with the painful sensory 
stimuli being conducted by the afferent nociceptors to projecting 
neurons on the spinal cord. From here the information about the 
location and intensity of the stimulus reaches the somatosensory 
cortex of the brain via thalamus. 
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The information conducted by the nociceptors after detecting a nociceptive stimuli (thermal, 
mechanical or chemical), is detected by specific receptors such as thermo-sensitive channels 
and mechano-transduction channels that are expressed by the nerve fibers. Voltage-gated ion 
channels are then activated in order to generate action potentials so the signals can reach the 
spinal cord and from there get to the brain where the pain is perceived (226-229). 
 
Persistent or chronic pain 
Similarly to the immune system, pain normally exerts an important protective role in the 
body. However, when persistent nociceptive input is dysregulated it can lead to 
hypersensitivity and pain signals become chronic and disabling. Processes such as allodynia 
(an innocuous stimuli is perceived as painful) or hyperalgesia (when the painful stimuli 
provokes more intense pain) become long-lasting and do not resolve as normally would 
happen. This is often the case for individuals suffering from RA and other inflammatory 
rheumatic disorders. Both central and peripheral mechanisms are responsible for the 
persistence of pain in these diseases (226-231).  
 
Peripheral pain mechanisms in RA are normally mediated by inflammatory factors 
(inflammatory pain). At the site of injury, a whole set of inflammatory molecules (released 
by nociceptors and non-neuronal cells) and cells accumulate. Macrophages, mast cells, 
neutrophils, platelets, fibroblasts and endothelial cells secrete and release pro-inflammatory 
and pro-algesic factors such as neurotransmitters, eicosanoids (prostaglandins, thromboxane, 
and leukotrienes), cytokines, chemokines and bradykinin. The nociceptors become activated 
since they contain receptors that bind the pro-inflammatory and pro-algesic factors, which 
lead to increased hypersensitivity to the injury and sometimes to persistent pain (226, 231, 
232). 
 
At the central level, the hypersensitivity that leads to chronic pain is mediated by processes 
that involve the central nervous system (central sensitization) (226, 231, 233).  
Some examples are: 
(1) Modifications in the receptor neurotransmission, for example glutamate/N-methyl-D-
aspartate (NMDA). When there is a persistent painful stimulus, nociceptors release 
glutamate and other neurotransmitters in the dorsal horn of the spinal cord. NMDA 
receptors that are usually at rest become activated and induce a signaling cascade that 
facilitates the transmission of pain to the brain. 
(2) Dysregulation of central pain modulatory pathways. Disinhibition if pathways involve 
GABAergic (gamma-aminobutyric acid) and Glycinergic neurotransmitters. When a 
persistent injury occurs, the neurotransmitters GABA and Glycine lose their inhibitory 
capacity and the regulation of pain is impaired.  
(3) Glial (microglia and astrocytes)-neuronal interactions. In a setting of persistent 
nociceptive input, a cascade of events activates microglial cells. These cells will 
thereafter secrete cytokines (e.g. TNF-α, IL-1β and IL-6) that will further enhance pain 
signals in the dorsal horn (229, 234). 
  
With the exception of cartilage, the sensory nerves (nociceptors) locate in all structures of the 
joint and surrounding areas (ligaments, tendon sheaths, muscles, adipose tissue and bone). 
These nociceptors are composed of A, A and C type of fibers and thus, both thermal and 
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mechanical stimuli are conducted from the skin and deep areas (joint and nearby regions) to 
the spinal cord. In addition, the nociceptors communicate with neurons located in supraspinal 
structures, and in this case only signals from the deep areas are conducted (235, 236). 
The gap between pain and inflammation in RA demonstrates that several molecular 
mechanisms are responsible for inducing pain in RA (236-239). Paper II of the thesis 
explores the role of ACPA as potential pain mediators. 
 
6. Idiopathic inflammatory myopathies 
Idiopathic inflammatory myopathies (IIM), collectively called myositis, encompass a group 
of chronic inflammatory diseases mainly affecting the skeletal muscle. Muscle weakness and 
low endurance as well as inflammatory cell infiltrates in muscle tissues are common 
manifestations. However, organs such as lungs, skin, joints, heart and gastrointestinal tract 
are also frequently involved (240, 241). A common clinical feature among patients affected 
with IIM is the difficulty of performing tasks that involve the proximal muscles. Daily 
activities, such as climbing stairs, getting dressed, lifting objects, bathing and combing the 
hair become hard to execute. Neck-flexor and pharyngeal muscles may be affected, leading to 
difficulties swallowing (dysphagia). The heterogeneous phenotypic nature of muscle biopsy 
features, autoantibodies presence and differential organ involvement, suggest different 
possible etiologies and distinct operating molecular pathways. These systemic diseases are 
classically termed as polymyositis (PM), dermatomyositis (DM), necrotizing myopathy (NM) 
and inclusion-body myositis (IBM) (68, 69, 242, 243). 
 
A concerted interaction between environmental factors and genetically susceptible 
individuals has been proposed as the main initial trigger of IIM. Evidences of such interaction 
lie, for instance, in the association between anti-Jo1 autoantibodies, HLA-DRB1*03 and 
smoking (57). In addition, a link between statins exposure and development of anti-HMGCR 
antibodies was shown for individuals carrying HLA DRB1*11:01 alleles (244). A viral 
aetiology has also been suggested, although no conclusive proofs are yet available. Different 
myopathies were reported to be associated with viral infections namely, human 
immunodeficiency virus, human T-cell lymphotropic virus type I, coxsackie virus 
cytomegalovirus, and Epstein-Barr virus (65-67, 245-248). 
 
Several molecular mechanisms, immune-mediated and non-immune mediated, may drive 
muscle damage (249, 250). In this thesis, immune-mediated mechanisms will be addressed 
and further discussed in the following sections. Emphasis will be given to the intricate and 
fascinating HisRS antigen and its cognate autoantibodies. 
 
IIM has a prevalence of 8.7-19/100,000 individuals and an incidence of 8-13/1 000 000 
person-years (251-254). DM and PM affect more women than men whereas IBM is more 
dominant in men. No distinction is seen in NM regarding gender. The age of onset can be, in 
the case of DM, during childhood or later in adulthood; PM on the other hand is more 
prevalent in adulthood as is the case for NM, although elderly individuals are also affected by 
NM; IBM tends to develop mainly in elderly over 50 years old (241, 255-257). 
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6.1 Classification and diagnostic criteria – clinical features and laboratory findings 
Several classification and diagnostic criteria have been proposed for IIM. However, the 
Bohan and Peter criteria are the most commonly used in clinical practice for the classification 
of PM and DM (Table 5a) (242, 243). The diagnostic criteria for IBM were proposed in 1995 
by Griggs and colleagues and are listed in Table 5b (258). 
 
Table 5a Diagnostic and classification criteria postulated by Bohan and Peter in 1975. The 
described criteria provide basis for the diagnosis and classification of DM and PM. 
Criterion Description 
1 Symmetrical muscle weakness (usually progressive) of limb-girdle and neck flexors 
2 
Muscle biopsy: Necrosis of type I and II muscle fibers; phagocytosis, regeneration, variation in 
fiber size, perifascicular atrophy and inflammation 
3 
Elevated serum levels of muscle-associated enzymes (creatine kinase, aldolase and 
transaminases) 
4 
Electromyographic abnormalities: myopathic potentials, short and low-amplitude polyphasic 
action potentials; Fibrillation potentials; high-frequency repetitive charges 
5 Cutaneous manifestations, concordant with myositis (heliotrope rash or Gottron’s papules) 
Definitive PM – Four criteria are fulfilled and no skin involvement; Definitive DM – Four criteria are 
fulfilled, together with skin rash. Probable PM and possible PM require fulfilment of three and two 
criterion without skin involvement, respectively. Probable DM and possible DM are diagnosed when two 
criteria and one criterion, together with skin rash, are presented. 
 
Table 5b Diagnostic and classification criteria postulated by Griggs and co-authors in 1995. 
The described criteria provide basis for the diagnosis and classification of IBM. 
Criterion Description 
A. Clinical features 
1. Duration of disease >6 months 
2. Age of onset >30 years old 
3. Muscle weakness - The proximal and distal muscles of arms and legs 
must be affected. In addition, the patients must show ≥1 of the following 
trades: i) Finger flexor weakness; ii) Wrist flexor weakness more serious 
than wrist extensor weakness; iii) Quadriceps muscle weakness 
B. Laboratory features 
1. Serum creatinine < 12 times normal 
2. Muscle biopsy: i) inflammatory myopathy with mononuclear cell 
infiltrates of nonnecrotic fibers; ii) vacuolated muscle fiber; iii) 
intracellular amyloid deposits or 15-18 nm tubulofilaments 
3. Electromyography must be consistent with features of inflammatory 
myopathies 
C. Family history 
Rarely IBM is observed in families. If there is a case, inflammation must be 
observed in the muscle biopsy 
Definitive IBM – Patients must exhibit all muscle biopsy characteristic features, irrespective of other clinical 
or laboratory findings. Possible IBM – The muscle only exhibits inflammation (and not the other typical 
muscle biopsy characteristics) and the patients fulfil A1, 2 and 3 and B1 and 3. 
 
Among other limitations, these criteria do not take into consideration the occurrence of 
autoantibodies. Up to 80% of IIM patients have autoantibodies in circulation (69, 259, 260). 
Some of these autoantibodies are not specific for myositis (myositis associated 
autoantibodies, MAA) and may even translate an overlap of several connective tissue 
disorders (CTD), e.g. PM or DM with scleroderma, SLE, Sjögren’s syndrome or RA (36, 
261). MAA are autoantibodies that target the autoantigens PM-Scl, TRIM21, U1-RNP 
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(RNA-binding domain on the peptide component of U1 ribonucleoprotein complex), and Ku 
(nuclear heterodimer composed of 70 and 80 kDa subunits of DNA binding protein). 
Autoantibodies directed to HisRS (anti-Jo1 or anti-HisRS) or other aminoacyl transfer RNA 
synthetases (anti-aaRS), anti-HMGCR, anti-MDA5 and anti-TIF1 autoantibodies are 
designated myositis specific antibodies (MSA) and are more specific for IIM (Table 6) (260, 
262-264). Evidence has been gathered clearly showing an association between certain MSA 
and distinct clinical phenotypes (e.g. anti-aaRS antibodies and anti-synthetase syndrome, 
ASS)(69, 260, 262). Love et al (265) proposed a different method to classify IIM patients 
whereby the presence of MSA was taken into account. In addition, the association among 
autoantibodies, different symptoms and genetic background was also investigated. The 
stratification based on occurrence of MSA created a more defined and homogenous 
classification in comparison to categorization into the classical clinical groups (e.g. PM, DM 
and IBM). The authors concluded that to have information on MSA status would benefit the 
interpretation of clinical symptoms, prognosis and clinical course. The diagnostic and 
prognostic value of MSA is currently well accepted. Table 6 lists MSA and associated 
clinical phenotypes. In the specific case of MSA that target aaRS, I will dedicate a separate 
section (6.2.1). 
 
Table 6 Myositis specific antibodies (MSA) and related clinical phenotypes (264). 
 
6.1.1 Dermatomyositis (DM) 
DM patients primarily exhibit skin manifestations such as heliotrope rash with edema (violet 
rash and swelling of eyelids) and Gottron’s papules (red slightly elevated rash over the 
knuckles). Additional skin manifestations may also be present and may sometimes overlap 
with other CTD: rash on the face, knees, elbows, neck, chest and shoulders. Overall, these 
symptoms may be accompanied or preceded by muscle weakness. The muscle biopsy in 
typical cases shows signs of inflammation (complement deposition, CD4
+
T cells, B cells and 
pDC infiltrates and MHC-I over-expression) in the layer of connective tissue that maintains 
the muscle fibers clustered (perimysium), around the vessels (perivascular) and around the 
bundles of fibers (perifascicular). Atrophy, necrosis and regeneration of the fibers may be 
seen particularly with a perifascicular localization (240, 241, 266, 267). Dermatomyositis 
may be associated with cancer. Up to 32% of DM patients were reported to develop cancer 
within 3 to 5 years after DM diagnosis (240, 268, 269). 
 
 
Autoantibody Clinical phenotype 
Anti-MDA5, Melanoma differentiation-associated protein 5 Amyopathic DM; ILD with poor prognosis 
Anti-SRP, Signal recognition particle Necrotizing myopathy 
Anti-TIF1-, Transcriptional intermediary factor 1  
Severe DM; Cancer-associated DM; Juvenile 
DM 
Anti-Mi-2, Nucleosome remodeling deacetylase complex Mild DM 
Anti-HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase 
Necrotizing myopathy (NM) 
Anti-SAE, Small ubiquitin-like modifier activating enzyme DM 
Anti-NXP-2, Nuclear matrix protein 2 Severe DM; cancer-associated DM 
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6.1.2 Polymyositis (PM) 
PM is many times diagnosed by exclusion of other myopathies. Similarly to DM, patients 
show proximal symmetric weakness, overlap with other CTD and presence of autoantibodies, 
myalgia and arthralgia. Muscle biopsy typically reveals inflammatory cells localized to the 
endomysium (connective tissue that surrounds each muscle fiber) with muscle fibers 
expressing MHC-I, surrounded by CD8
+ 
T cells, macrophages, myeloid DCs and less 
frequently plasma cells, and no vacuoles in the fibers. Degeneration or regeneration of muscle 
fibers is also common in PM but with a scattered pattern in the fascicle (240, 241, 257). 
 
6.1.3 Inclusion body myositis (IBM) 
IBM develops gradually with early involvement of both proximal and distal muscles and 
early muscle atrophy. It may also be associated with a CTD. Muscle biopsy features are 
similar to PM with addition of rimmed vacuoles in the muscle fibers and with inclusions in 
the nuclei or cytoplasm. Autoantibodies are less common in IBM but may be present in up to 
20% of the patients, often anti-Ro60/52 (270). A new IBM associated antibody, anti-cytosolic 
5'-nucleotidase 1A, has recently been discovered to occur in 33-76% of IBM patients (271, 
272). Very recently these autoantibodies were also demonstrated in 15% of DM, 23% of 
Sjögren's syndrome and 14% SLE patients (273). If IBM is a primary inflammatory 
myopathy such as DM and PM, is still under debate (274, 275). 
 
6.1.4 Necrotizing myopathy (NM) 
NM associates with malignancy, CTD or statin use. Patients have muscle weakness and 
autoantibodies directed against HMGCR or signal-recognition particle (SRP). Muscle fiber 
necrosis and deposits of complement components in the capillaries portrait NM muscle 
biopsy. Inflammatory cells are scarce or absent (240, 241, 257). 
 
6.2 Anti-synthetase syndrome (ASS) 
The clinical entity characterized by the simultaneous presence of anti-aaRS autoantibodies, 
inflammatory myopathy, ILD, arthritis, fever, Raynaud’s phenomenon (RP, limited blood 
supply to areas such as fingers and toes) and mechanic’s hands is termed anti-synthetase 
syndrome (ASS, Figure 7, upper panel) (276). To date, eight aaRS have been documented as 
autoantigenic targets, and therefore eight correspondent autoantibodies were described: Anti-
histidyl-RS or aJo1, the most common; anti-threonyl-RS or aPL-7; anti-alanyl-RS or aPL-12; 
anti-glycyl-RS or aEJ; anti-isoleucyl-RS or aOJ; anti-asparaginyl-RS or aKS; anti-tyrosyl-RS 
or aHa and anti-phenylalanyl-RS or aZo (Figure 7, lower panel). 
 
From the clinical features that characterize ASS, one of the most frequent symptoms, also 
contributing to high morbidity and mortality, is ILD (277, 278). It has been reported that 
between 67-100% of ASS patients are affected by ILD (279-282). Some authors claim that 
this percentage depends on the anti-aaRS antibody specificity. In fact, evidence suggests an 
association between the presence of certain anti-aaRS and the clinical presentation of ILD, 
which may suggest different sub-phenotypes within ASS (279, 281, 283-285). For example, 
aPL-7 appears to be more associated with muscle weakness and heliotrope rash, whereas aJo1 
has been correlated with ILD, arthritis, mechanic hands and muscle weakness. Anti-PL-12 
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was described to preferentially link to RP and isolated ILD; Anti-KS and aOJ have also been 
associated with isolated ILD (285-288). Intriguingly, anti-aaRS antibodies rarely overlap in 
the same individual. Histopathologically, ASS is characterized by regeneration, 
fragmentation and inflammation (macrophages and lymphocytes infiltrates) of the perimysial 
and perifascicular areas as well as increased protein expression of MHC-I (Figure 7) (289-
291). Similar histological findings can be observed either when myositis is diagnosed alone 
or in the case of ASS diagnosis. 
Although ASS has been considered an individual clinical entity, a recent meta-analysis 
demonstrates a large overlap between clinical features of anti-aaRS-positive patients and 
those having anti-Pm-Scl autoantibodies. Based on their findings, the authors question the 
validity of ASS diagnosed as an entity (292). 
 
Figure 7 Myopathology of ASS (left panel) and 
anti-aaRS autoantibodies (Table below). 
Illustrative examples of ASS (pictures A, C, E, G) 
and DM (pictures B, D, F and H) histopathology. 
A, Regenerating fibers and infiltrates in 
perimysium and perifascicular endomysium; B, 
Perifascicular atrophy; Neural cell adhesion 
molecule expressing-myofibers in the 
perifascicular layers in C and in individual or 
grouped perifascicular layers in D; MHC-I 
expressing fibers in E (more pronounced) and F; 
G and H, Macrophages precursor (CD68) 
expression mainly in the perimysium; I, 
Raynaud’s phenomenon in an aPL7 positive 
patient; J, High-resolution computed tomography 
from the lungs of an aJo1+ patient.  
Images A – H were reprinted with permission from 
BioMed Central, Aouizerate J et al. Acta 
Neuropathologica Communications 2014, 2:154. 
Images I and J were reprinted with permission from 
@ERS publications, Jean-Christophe Lega et al. 
European Respiratory Review Jun 2015, 24 (136) 216-
238; DOI: 10.1183/16000617.00002015. 
 
Autoantibody Frequency in IIM (%) References 
Anti-histidyl RS (aJo1) 15-36 (285, 293, 294) 
Anti-threonyl RS (aPL-7) 2-18 (285, 295-297) 
Anti-alanyl RS (aPL-12) 2-11 (285, 297-299) 
Anti-glycyl RS (aEJ) 2-23 (285, 297, 300) 
Anti-isoleucyl RA (aOJ) <5 
(285, 287, 301, 
302) 
Anti-asparaginyl RS (aKS) <8 (285, 303, 304) 
Anti-tyrosyl RS (aHA) <1 (305) 
Anti-phenylalanyl RS (aZo) <1 (306) 
 
6.2.1 The case for HisRS and anti-HisRS antibodies 
Histidyl-tRNA synthetase (HisRS or Jo1) is an important enzyme for protein synthesis. 
HisRS catalyses the attachment of histidine (standard amino acid) to its cognate transfer RNA 
(tRNA
His
). The human HisRS gene locates on chromosome five, and four main isoforms are 
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produced by alternative splicing. Several natural variants (a mutation or a polymorphism) 
have also been documented. For instance, mutations located at positions 454 and 137 were 
found in patients with Usher syndrome 3B (progressive hearing and visual loss during 
childhood) and peripheral neuropathy (distal motor and sensory dysfunction) (307, 308). 
 
Higher eucaryotic HisRS, as well as other aaRS, were appended with an additional domain 
not comprised earlier in the phylogenetic tree. This domain, termed WHEP domain, is 
composed of 60 amino acids and locates in the N-terminal. The main human isoform studied 
(and also used in this thesis) is composed of 509 amino acid residues; it has a molecular 
weight of 57.4 kDa, and exists as a homodimer (~115 kDa). Natural splice variants (SV) have 
been reported and are indicative of an evolutionary pressure to perform additional non-
canonical functions (309, 310). Other aaRS were also described to have alternative fragments 
and to be implicated in functions other than protein synthesis (311). HisRS structure is 
depicted in Figure 8. 
 
Antibodies directed to HisRS (aJo1) are the most common type of MSA (Figure 7, table in 
lower panel). Most remarkable is the association with ILD whereby up to 90% of the patients 
with aJo1 in circulation present signs of ILD (279, 312). Whether the autoantibodies are 
involved in disease initiation and development is still an open question. Yet, several 
observations suggest a potential role: aJo1 serum levels correlate with disease activity and 
may precede the clinical symptoms (313-315); HLA-DRB1*03 genotype is associated with 
smoking and the presence of aJo1 (57); aJo1-positive sera induces IFN-α production by pDCs 
(270); In a conditional MHC-I animal model, mice developed myositis–like disease, and 
clinical features such as aJo1 were observed (316). Furthermore, MHC-I as well as type I 
IFN-induced genes are highly expressed in muscle fibers from myositis patients in 
comparison to normal muscle (317, 318). Knowing that type I IFN are strong MHC-I 
inducers (319), it is tempting to suggest that one mechanism by which aJo1 may mediate 
pathogenesis is via IFN (further discussed in results and discussion section).  
 
Anti-Jo1 autoantibodies bind both HisRS as well as the complex HisRS-tRNA
His
, and display 
higher affinity to HisRS if the enzyme has been pre-incubated with tRNA thus, acting as an 
inhibitor of HisRS enzymatic activity (315, 320). A truncated version of HisRS lacking the 
amino acids 1-60 was revealed enzymatically inactive and no longer antigenic (321). These 
experiments were crucial to understand that one of aJo1 main epitopes is located near the N-
terminal. It was also shown that aJo1 from IIM patients recognize more than one epitope 
within HisRS (both conformational dependent and indepedent), suggesting that the antibodies 
undergo epitope spreading and may not result from a cross-reactive antigen (e.g. virus) (315, 
322). Different myositis patients recognize different HisRS epitopes (322). In addition, aJo1 
were shown to be mainly IgG1 isotype and to undergo affinity maturation and class switching 
(323). Taken together, these studies indicate that aJo1 may have a relevant role in IIM (313, 
315, 320-324). 
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Figure 8 HisRS structure. a and c HisRS is composed of three main domains: N-terminal WHEP domain 
(comprises the first 60 amino acids), a core catalytic domain (CD) and a C-terminal anticodon binding domain 
(ABD); b A natural splice variant (SV) lacking the entire CD, thus joining the N-terminal WHEP to the C-
terminal ABD domains, was first described in 2012 and termed HisRSΔCD. HisRSΔCD exists as a 171 amino 
acid monomer. An additional and also previously undescribed SV is the WHEP domain, solely composed of the 
first 60 amino acid (HisRS
WHEP
); c Motifs 1, 2 and 3 (colored green, blue and brown, respectively) represent 
conserved sequences; d left panel, lung from healthy donors and d right panel, skeletal muscle from myositis 
patients express messenger RNA that encodes for HisRS
WHEP 
SV; e Anti-Jo1+-depleted serum recognizes 
HisRSΔCD and HisRSWHEP SV whereas minimal reactivity was observed for CD and ABD. The authors 
claimed that the two SV contain the major anti-Jo1 epitopes. Figure 8 contains sections from Figure 1 and 2 
published by Zhou JJ et al. J Biol Chem. 2014 Jul 11;289(28):19269-75 (Images available from JBC publications). 
 
Albeit no conclusive proof of the pathogenic involvement of aJo1 in initiation and 
development of IIM with lung involvement, HisRS, on the other hand, has been suggested to 
drive tissue specific autoimmunity and damage. In fact, one may speculate whether the 
immune system would employ aJo1 as an attempt to neutralize HisRS damages. Figure 9 
illustrates a summary of the current lines of investigation whereby HisRS is shown to be a 
crucial player that drives lung and muscle autoimmunity (325-327). The work done in this 
thesis will add some more pieces to the understanding of autoimmunity in IIM with lung 
involvement (Paper V). Our findings are described under sud-heading 4 of the section Results 
and Discussion and illustrated in Figure 17 of Conclusions and Future Perspectives section. 
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Figure 9 Insights into HisRS-mediated mechanisms – impact on IIM with lung involvement. The 
hypothesis of HisRS involvement in IIM with lung involvement starts with a question mark (1). After years of 
research the trigger(s) leading to IIM remain unidentified. Environmental factors such as smoking or viral 
infections may be the lead word, though not yet conclusive. (2) In certain individuals, when such trigger is 
present and together with a particular genetic background (e.g. HLA-DRB1*03 (57)), HisRS is cleaved by GrB 
released by CD8
+
T cells in the lungs. The GrB cleavage site in HisRS is located close to the main epitope, near 
the N-terminal (328). In addition, a HisRS SV containing the first 60 amino acids of the protein (HisRS
WHEP
) is 
also expressed in high amounts in the lung (310), suggesting that in this tissue HisRS is antigenic and amenable 
to initiate a local autoimmune response. As local iDC and macrophages take up HisRS, they become activated 
and migrate to the lymph nodes (3) to present HisRS peptides to T cells. T and B cells are activated, proliferate, 
undergo clonal expansion and release pro-inflammatory cytokines. As B cells differentiate into plasma cells, 
aJo1 are produced and travel to the blood stream (4). Naïve T and B cells will also reach the target organs. Sera 
from aJo1+ individuals induce expression of intercellular adhesion molecule-1 (ICAM-1) (329) which in turn 
may foster the inflammatory flux namely, activated T cells that will penetrate the endothelial cells and reach 
peripheral lymphoid tissues (4). Type I IFN seems to have an important role in HisRS-mediated autoimmunity. 
Sera or total IgGs from aJo1+ sera induce increased IFN production by peripheral blood mononuclear cells 
(270). Anti-Jo1+ patients with ILD have high levels of B cell activating factor (BAFF), which is known to be a 
potent IFN inducer (330). In line, aJo1+ patients with ILD show IFN--inducible chemokine (CXCL9 and 
CXCL10) patterns, distinct from those observed in anti-SRP+ myositis patients with no ILD (279). (5) Muscles, 
the other target microenvironment, from myositis patients undergo regeneration in order to replace injured fibers, 
leading to over-expression of HisRS (98). HisRS displays pro-inflammatory properties by activating CCR5-T 
lymphocytes and iDC, thereby inducing inflammatory cell recruitment to the damaged muscle (99). As damaged 
fibers are being replaced constantly, the over-expression of HisRS directs the immune response against the 
regenerating fibers thus creating a feed-forward loop that leads to additional HisRS protein expression and 
ultimately to muscle injury (5). CD4
+
 and CD8
+
T cell infiltrates release cytotoxic granules (containing perforin 
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and granzymes) that cause fiber necrosis. HisRS was described to mediate TLR2 and 4 activation which suggests 
an intrinsic capacity to induce myositis in an adaptive-immunity independent manner (331, 332). Macrophages, 
DC, pDC and T and B lymphocytes mount a local immune response that perpetuates inflammation and tissue 
damage (5). A possible link between the lung and the muscle in myositis is the T cell receptor usage, shown to 
be shared between the two organs (333) (2, 5). IIM patients with ILD were described to promote defective 
development of NETs, which may be an additional explanatory mechanism for the development of lung disease 
in these patients (334) (2).  
 
7. Therapies 
7.1. Rheumatoid arthritis 
The spectra of treatments used for RA have significantly developed in the last decades. Due 
to an advanced knowledge on molecular mechanisms, more targeted therapies have been 
proposed and some of them have already being implemented. 
By definition, synthetic DMARDs (disease modifying anti-rheumatic drugs) need to have an 
impact on inflammation and reduce joint damage (reduce acute-phase proteins and 
autoantibody levels and delay erosions, evaluated by radiological assessment) (335, 336). 
Methotrexate (MTX) and glucocorticoids are two of the most common DMARDs used in 
clinical practice. Glucocorticoids (GluC) are steroid hormones that effectively suppress 
synovial joint inflammation by acting at various molecular levels like inhibition of cytokine 
transcription or induction of apoptosis in inflammatory cells (337). Although effective, GluCs 
cause serious side-effects (338-340). Methotrexate is an anti-metabolite that inhibits enzymes 
responsible for the nucleic acids and protein synthesis, therefore a powerful modulator of the 
cell metabolism. It is well tolerated and acts effectively limiting symptomology and relieving 
radiographic progression. However, gastrointestinal problems and pulmonary interstitial lung 
disease are potential serious side-effects (338, 340, 341). Biological DMARDs (Table 7) 
have gain importance in the past decade as RA molecular mechanisms became unraveled. 
These biological agents mimic endogenous components such as antibodies and receptors. 
 
Table 7 Biological agents used for the treatment of RA 
Biological agent  Structure Target 
Infliximab Human chimeric monoclonal antibody TNF 
Adalimumab Fully human monoclonal antibody TNF 
Etanercept Recombinant TNF receptor fused to a human Fc protein TNF 
Golimumab Human monoclonal IgG1 TNF 
Certolizumab pegol Recombinant Fab’ conjugated to polyethylene glycol TNF 
Anakinra Recombinant IL-1 receptor antagonist IL-1 receptor 
Tocilizumab Human receptor antibody IL-6 receptor 
Abatacept Fc region from IgG1 fused to CTLA-4 T cell modulation 
Rituximab Chimeric monoclonal antibody anti-CD20 B cell depletion 
 
Five TNF inhibitors are currently in use (340, 342-344). Treatment with TNF inhibitors 
successfully decreases synovitis and bone destruction, thereby preventing physical disability. 
Furthermore, improved clinical efficacy has been shown when combined therapy is 
administered (e.g. MTX + TNF inhibitors). Other biological agents (Table 7) have proven 
beneficial treating inflammation and bone destruction (345-347). Although promising 
therapies, a fraction of patients treated with biologicals do not respond at all and some 
develop complications such as infections (338, 348). 
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Pain 
In order to reduce pain, RA patients are often given non-steroidal anti-inflammatory drugs 
(NSAID, e.g. aspirin and ibuprofen). The mechanism of action involves inhibition of 
cyclooxygenase (COX)-1 and 2, as these enzymes are responsible for the synthesis of 
prostaglandins. Administration of DMARDs is also used for pain management in RA. 
However, and as described in the section above, pain does not only result from inflammation 
and damaged tissue, therefore alternative and/or complement analgesics are in need (225, 
236).  
 
7.2. Idiopathic inflammatory myopathies 
Because IIM are rare conditions clinical trials are difficult to design due to the low prevalence 
and incidence and heterogeneous clinical presentation. Additionally, the lack of molecular 
knowledge responsible for disease mechanisms limits the design of more personalized drugs. 
Therapy in IIM aims to improve muscle strength, prevent disease progression and reduce 
additional organ damage. The first line treatment for PM and DM include high doses of 
GluCs (e.g. prednisone) for several weeks followed by slow tapering (349, 350). Often 
immunossuppressive agents such as azathioprine and MTX are given in combination to 
GluCs (241, 257, 351, 352). When this approach fails either due to side-effects or low 
improvement of physical disability, additional immune-modulating agents are used. Those 
agents consist of cyclosporine, mycophenolate mofetil, tacrolimus and intravenous 
immunoglobulins (350, 353, 354). All these compounds interfere with proliferating T and B 
cells. Azathioprine is metabolized through a number of steps that ultimately inhibit de novo 
synthesis of purines and consequently DNA (355), mycophenolate mofetil inhibits inosine-5'-
monophosphate dehydrogenase which is an enzyme responsible for purine synthesis (356) 
and tacrolimus inhibits a calcium-dependent protein important for IL-2 signaling (357). 
Biological agents have also been used in myositis although, so far, with unclear or no effects 
(349, 350). 
Increasing number of evidences demonstrate the benefit of adding physical exercise to the 
pharmacological treatment. Exercise appears to contribute to improved muscle performance 
through various mechanisms: up-regulation of genes involved in muscle growth and aerobic 
pathways; down-regulation of inflammation-related genes; alterations in the type of muscle 
fibers; and enlargement of muscle fiber area (358-361). 
 
7.3. A non-conventional approach – Targeting autoantibodies for disease amelioration 
Albeit autoimmune conditions share a dysregulation of the immune system, distinct 
molecular mechanisms account for the disease development. Different genetic backgrounds, 
environmental exposures or other stochastic factors dictate the outcome phenotype of these 
disorders. The development of personalized therapies has been possible due to a rise in the 
molecular knowledge behind the classification of sub-populations of patients such as for 
example, ACPA+ and ACPA- RA or RF+ and RF- RA. Rituximab was reported to be more 
efficient on seropositive RA (ACPA+ and RF+) in comparison to the seronegative population 
(ACPA- and RF-) (346, 362, 363). Although rituximab is appreciated as an effective B-cell 
depleting agent leading to disease progression arrest, naïve B cells were demonstrated to 
persist, re-populate and induce relapse (364). An attractive alternative approach is the direct 
target of pathogenic autoantibodies by small molecules such as peptides or nucleotides (365). 
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Such principle has been explored in conditions such as cardiomyopathy whereby myocardial 
damage is known to be caused by autoantibodies towards cardiac 1-adrenergic receptor 
(366). In the case of RA, endogenously citrullinated peptides could be engineered into stable 
compounds. The binding of these compounds to ACPA would restrict perpetuation of 
inflammation and therefore improve disease outcome (365, 367). This strategy was explored 
in paper III and IV of the thesis and will be further discussed in results and discussion section. 
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AIMS 
Inflammatory autoimmune diseases are chronic disabling conditions that affect organs such 
as joints, muscles, lungs and skin. In order to treat or prevent these diseases we need a better 
understanding of the contributory pathogenic events. Hence, the overall aims of this thesis 
were to provide insights into different molecular mechanisms underlying rheumatoid arthritis 
and myositis as well as to develop compounds that counteract the effects of autoantibodies by 
blocking the binding to their cognate targets. 
 
Specific aims   
Paper I: Development of a new methodology for ACPA purification from plasma and 
synovial fluid in order to use the antibodies as a molecular tool to investigate their mode of 
action. 
 
Paper II: Investigate if purified human ACPA induce pain in mice. 
 
Paper III: Evaluate if endogenously citrullinated fibrinogen peptides are autoantigenic and 
whether those peptides could be utilized to block human ACPA. 
 
Paper IV: Development of new stable compounds intended to specifically block 
citrullinated fibrinogen-reactive ACPA and therefore be employed as a therapy and as a 
diagnostic tool. 
 
Paper V: Investigate the contribution of the antigen HisRS and cognate autoantibodies in 
myositis with lung involvement. 
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EXPERIMENTAL PROCEDURES 
1. Patients (Papers I-V) 
Samples from patients that visited the Rheumatology Clinic at Karolinska University 
Hospital (Stockholm, Sweden) and fulfilling the ACR/EULAR criteria for RA (122-124) 
were collected. Selection of patients for isolation of anti-CCP2 IgG was based on anti-CCP2 
positive reactivity. Plasma (n=62), sera (n=10) and synovial fluid (SF, n=34) from the 
selected, non-paired RA patients, were collected and kept at −80°C until processed. Synovial 
fluid was taken from patients that underwent arthrocentesis (procedure executed with a 
needle in order to aspirate fluid from a joint). The purified autoantibodies were employed in 
several experiments that compose papers I to IV. For Paper III, sera from 927 (402 CCP2 
positive and 525 CCP2 negative) newly diagnosed RA patients (within one year of 
appearance of first symptoms), were used. Simultaneously, 461 healthy controls (HC) sera 
from the Swedish population registry were randomly chosen in order to match age, sex, and 
residential area. All samples were taken within the context of the Epidemiological 
Investigation of RA (EIRA) case-control cohort. 
In paper V, sera from myositis (PM, DM and IBM) patients (aJo1+ (n=38) and aJo1- (n=15)) 
were collected in the Rheumatology Clinic at Karolinska University Hospital. Paired BAL-
serum samples were collected from myositis, sarcoidosis and HC (n=7-8 per group) in the 
Respiratory Medicine Unit at Karolinska University Hospital. The bronchoscopy was 
performed according to published procedure (368). Presence or absence of anti-Jo1 
antibodies was assessed by Elisa and/or Line-blot and/or WB/IP assays (369, 370). Satellite 
cells for in vitro experiments were derived from the muscle biopsy of a DM patient, as 
described in Pandya et al (under revision). Myositis patients fulfilled the Bohan and Peter 
criteria for diagnosis of PM and DM, and Griggs criteria for diagnosis of IBM. Criteria 
designed by the World Association of Sarcoidosis and other Granulomatous Disorders 
(WASOG) (371) was applied for sarcoidosis. 
 
2. In vitro methodology 
2.1. Peptides (Papers III and IV) 
The following peptides were synthetized in house:  
 
Table 8 Sequences of linear peptides utilized in paper III 
Peptide name Peptide sequence 
Arg573 HHP GIA EFP SRG KSS SYS KQF 
Cit573 HHP GIA EFP SXG KSS SYS KQF 
Arg591 SKQ FTS STS YNR GDS TFE SKS 
Cit591 SKQ FTS STS YNX GDS TFE SKS 
Arg72,74 APP PIS GGG YRA RPA KAA AT 
Cit72 APP PIS GGG YXA RPA KAA AT 
Cit74 APP PIS GGG YRA XPA KAA AT 
R – Arginine; X – Citrulline. 
 
For the sake of clarity the nomenclature of peptides in paper III was altered. Table 9 lists all 
the peptides and nomenclatures used in paper III and IV. 
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Table 9 Nomenclature of peptides utilized in paper III and IV 
Peptide name paper III Peptide name paper IV 
Cit573 [Cit573]fib(563-583) 
Arg573 [Arg573]fib(563-583) 
Cit573Lin1 [Cit573]fib(566-580) 
Cit573Lin2 [Cit573]fib(567-577) 
Cit573Cyc c[Cit573]fib(563-583) 
Peptides only included in paper IV  
c[Cit573]fib(566-580)  
c[Arg573]fib(566-580)  
c[Ala573]fib(566-580)  
s1[Cit573]fib(566-580)  
s1[Arg573]fib(566-580)  
s2[Cit573,Arg575]fib(566-580)  
s3[Cit573,Arg575]fib(566-580)  
Cit, citrulline; Fib, fibrinogen; Arg, arginine; Lin1 – Linear form 1, which is the truncated Cit573 
peptide with 15 amino acids residues; Lin2 – Linear form 2, which is the truncated Cit573 peptide 
with 11 amino acids residues; Cyc – cyclic; C, cyclic; Ala, alanine; s, sunflower trypsin inhibitor 1 
(SFTI-1); s2 and s3 are mutant peptides of s1. 
 
S1[Cit573]fib(566-580) peptide was synthetized by grafting the truncated linear peptide 
[Cit573]fib(566-580) into the stable cyclic peptide sunflower trypsin inhibitor-1 (SFTI-1). S2 
and s3 are mutants of s1 in which a Lys was inserted in different parts of the secondary loop 
of SFTI-1. In addition, the Lys in the position 575 was exchanged to an Arg in order to avoid 
unspecific binding. S2[Cit573,Arg575]fib(566-580) was used to create an affinity column 
(methods 2.3) and to develop an in house ELISA (methods 2.4.2). 
 
2.2. Expression and purification of recombinant human HisRS (Paper V) 
Recombinant human HisRS (rHisRS) was overexpressed in Escherichia coli (E. coli) 
BL21(DE3)pLysS competent cells. Recombinant HisRS was purified from the cytosolic 
fraction of bacteria lysate by sub-cellular fractionation followed by hypdroxyapatite and 
strong anion exchange chromatography. Thereafter, rHisRS was simultaneously filtered and 
buffer exchanged to PBS using 30 kDa filter tubes. Purity was assessed by SDS-PAGE 
followed by Coomassie blue and silver staining as well as by WB using a commercial 
primary antibody (Anti-HisRS N-terminal). Mass spectrometry analysis confirmed the 
recombinant protein as human HisRS. No endotoxin contamination was found (<0.05 
EU/mL). 
 
2.3.  Affinity purification of autoantibodies from plasma, sera and SF (Papers I – V) 
The development of a methodology for isolation of autoantibodies from patients’ material 
(blood and SF) was one of the most important techniques used throughout my PhD studies 
(purification scheme is illustrated in Figure 13, under sub-heading 1 of results and discussion 
section). These autoantibodies were utilized in all papers and manuscripts included in the 
thesis and are continuously used in additional studies, not addressed herein. The main core of 
this methodology was applied for the purification of anti-CCP2 IgG (also termed ACPA), 
anti-citrullinated fibrinogen α chain derived peptide [Cit573]fib(563-583) IgG (anti-Cit573 
IgG) and anti-Jo1 IgG, and includes two main steps: isolation of total IgG followed by 
isolation of specific autoantibody fine-specificities utilizing in house prepared affinity 
columns (CCP2, s2[Cit573,Arg575]fib(566-580), and rHisRS columns). To prepare 
37 
 
s2[Cit573,Arg575]fib(566-580) and HisRS affinity columns one mg of either 
s2[Cit573,Arg575]fib(566-580) peptide or rHisRS were coupled to 1 mL N-
hydroxysuccinimide activated pre-packed sepharose columns. 
Synovial fluid samples were treated with hyaluronidase, centrifuged at 3000 g during 5 
minutes and precipitated with saturated ammonium sulfate. Before applying the samples to 
HiTrap Protein G HP columns, SF-derived proteins were dialyzed against PBS and plasma 
and sera were centrifuged at 3000 g for 5 minutes and diluted 1:5 (v/v) in PBS. As total IgGs 
were eluted with 0.1 M glycine-HCl pH 2.7 the pH was immediately adjusted to ~7.4 (1 M 
Tris, pH 9) and the antibodies were dialysed against PBS. Anti-CCP2 IgG, anti-Cit573 IgG 
and anti-Jo1 IgG were isolated by applying total IgGs to CCP2, s2[Cit573,Arg575]fib(566-
580) or HisRS affinity columns and further processed as described for total IgGs. Non-CCP2, 
non-s2[Cit573,Arg575]fib(566-580) and non-HisRS-reactive IgGs were collected to use as 
controls (Flow Through, FT). Recovery, purity and specificity of eluted autoantibodies were 
confirmed by Coomassie blue staining, WB/dot-blot or enzyme linked immunosorbent assay 
(ELISA) after antibodies have been buffer exchanged to PBS and sterile filtered. The 
concentration and proportion (%) of anti-CCP2 IgG, anti-Cit573 IgG and anti-Jo1 IgG in 
plasma/sera or SF was estimated by measuring the absorbance at 280 or 595 nm, taking into 
consideration the amount of total IgG loaded into each affinity column and the amount of 
eluted antibodies.  
Throughout the thesis anti-citrullinated protein/peptide antibodies affinity purified according 
to the method described above will be called either ACPA or anti(a)-CCP2 IgG. Several 
ACPA/aCCP2 IgG pools were prepared and utilized in Paper I-IV. 
 
2.4.  ELISA (Papers I, III, IV and V) 
The ELISA is a method vastly used both for research purposes as well as diagnostics in the 
clinical practice. This technique enables the detection and quantification of proteins in a 
complex matrix such as sera or plasma. The principle of an ELISA is based on the reaction 
between antigen and antibody. This type of interaction is also widely applied by different 
methodologies such as WB, dot-blot and IP, as discussed in the following sections. During 
my PhD studies I performed commercial ELISAs such as the anti-CCP2 ELISA and 
previously developed in-house ELISAs such as anti-Cit573 ELISA. Also, I established new 
ELISA assays for detection of anti-Cit573 IgG using the new compound 
s2[Cit573,Arg575]fib(566-580), detection of anti-HisRS IgG, IgA and IgM as well as a 
sandwich ELISA to detect and quantify HisRS antigen in plasma/sera, BAL and supernatants 
from myoblasts and myotubes. Cutoff values for ELISA were calculated as the average OD 
plus two times the standard deviation (SD) calculated from the OD given by the control 
group. 
 
2.4.1. Competition assays (Paper III and IV) 
Competition experiments were developed in order to assess ACPA inhibition by different 
citrullinated fibrinogen-derived peptides. Peptides derived from the fibrinogen α (Arg/Cit573, 
Arg/Cit591) and β chains (Arg/Cit72, Arg/Cit74), previously identified in the synovial tissue 
from RA patients (Table 8 (372)) were tested in the assay. Figure 10 illustrates the 
competition experiment developed. 
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Figure 10 Serial increasing amounts of each peptide (0.016 - 320 nmol in 225 μl of dilution buffer, citrulline, 
arginine and alanine versions) were incubated for one to two hours with two different affinity purified anti-CCP2 
IgG pools (8 nM). Autoantibody pools comprising aCCP2 IgG antibodies were isolated from sera and plasma 
samples collected from RA patients (Methods 2.2). Antibodies mixed with peptides were subsequently added to 
CCP2 or s2[Cit573,Arg575]fib(566-580) plates. After incubation with anti-human IgG antibody, absorbance at 
450 nm was recorded. Percentage (%) of ACPA inhibition was calculated according to the following formula: 
 
ACPA inhibition (%) = 100-[(OD450nm ACPA + peptide)/OD450nm ACPA with no peptide]*100,  
 
considering ACPA incubation with no peptide as 100% of maximum OD450nm obtained.  
Additionally, aCit573 IgG isolated from three RA individuals (Methods 2.3) known to contain this specific 
ACPA reactivity were also tested in the competition assay. 
 
Truncated, cyclic and grafted versions of the linear peptide [Cit573]fib(563-583) were also 
tested (Structures and terminology are listed in Tables 8 and 9, Methods 2.1 and in Figure 14 
under sub-heading 3 of Results and Conclusions). 
 
2.4.2. Anti-Cit573 IgG ELISA using a novel compound (Paper IV) 
In order to ensure that s2[Cit573,Arg575]fib(566-580) would bind to 96 well plates through 
the N-terminal, Nunc® Immobilizer™ Amino plates were chosen. Plates were coated with 
s2[Cit573,Arg575]fib(566-580) (5 μg/mL peptide diluted in 100 mM Na2CO3 pH 9.6) 
overnight at 4°C, washed three times with PBS containing 0.05% Tween, and blocked for 60 
minutes with PBS/1% BSA. Diluted plasma (1:100) was added to blocked plates for one to 
two hours at room temperature followed by incubation with anti-human IgG antibody 
(1:10,000, one hour at room temperature). The substrate 3,3’,5,5’-Tetramethylbenzidine was 
added to washed plates and the enzymatic reaction was stopped with 1 M H2SO4. Absorbance 
at 450 nm (reference filter 650 nm) was recorded. 
 
2.4.3. Anti-Jo1 Igs ELISA (Paper V) 
Anti-Jo1 Ig isotypes were investigated both in BAL and sera from myositis patients and HC 
similarly to what was described above for anti-Cit573 IgG (Section 2.4.2). For detection and 
quantification of aJo1 Igs (IgG, IgA and IgM), sera was diluted 5000x for aJo1 IgG, 890x for 
aJo1 IgA and 500x for anti-Jo1 IgM ELISAs. Secondary antibodies were diluted 500x and 
50x for detection of human IgG/IgA and IgM, respectively. Absorbance at 405 nm (p-
nitrophenyl phosphate substrate) was recorded between 15 and 45 minutes and compared to 
absorbance given by total Igs ELISA. Anti-histidyl tRNA synthetase autoantibodies will be 
denoted anti(a)-Jo1 IgG, aJo1 or anti-HisRS IgG throughout the thesis. 
 
2.5.  Western blot and dot-blot (Paper I, II and V) 
Western blot (WB) is an analytical technique, which allows identification and semi-
quantification of specific proteins in complex protein mixtures. During my PhD studies I 
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have widely applied WB to various purposes. In Paper II the localization of human antibodies 
(anti-CCP2 IgG; CCP2 FT IgG and HC IgG) that have been injected in mice was investigated 
in homogenized mice tissues and plasma using a single antibody that targets human IgG. In 
Paper V, WBs were performed in plasma, sera and BAL from myositis patients, sarcoidosis 
patients and HC and also in eluates obtained by immunoprecipitation of plasma, sera and 
BAL from the same individuals in order to investigate the presence of extracellular HisRS. 
Figure 11 illustrates the WB procedure. 
 
Figure 11 Sample preparation (1) for WB requires different approaches depending if working with fluids (sera, 
plasma or BAL), tissues or cells. Tissues and cells were first treated (homogenized and sonicated) with protein 
extraction buffer supplemented with protease inhibitors. Extracted proteins were reduced and denatured and 
separated using electrophoresis according to their molecular weights (2). Subsequently, proteins were 
electroblotted from the gel onto a membrane (nitrocellulose or polyvinylidene fluoride) (3) and non-specific 
binding of the membranes was blocked with 5% non-fat dry milk in PBS or TBS containing 0.1% Tween 20 (4). 
Incubation with the antibody targeting the protein of interest (Primary Ab) generally took place overnight at 4°C 
(5). In the case of WB in Paper II, membranes were incubated with anti-human IgG for one hour at RT, washed 
and directly developed as described below. The last step involves the incubation of the protein-containing 
membranes with the secondary antibody (one hour at RT, 6). This antibody is chosen based on the reactivity 
against the animal where the primary antibody was raised in. Lastly, membranes were developed and images 
acquired using X-ray films. Native gels required non-reducing/denaturing gels and buffers (NativePAGE Novex 
4-16% Bis-Tris) but the remainder protocol follows the descriptions above.  
 
Dot-Blot  
Dot-blot is a simplified version of WB. One advantage of using dot-blot is the fact that low 
abundant proteins present in complexes matrixes such as sera and plasma can readily be seen 
in the membranes, whereas sometimes no signal can be detected on WB (on both native and 
denaturing/reducing conditions). This method was applied in Paper V: for dot-blot 
experiments plasma, sera or BAL were directly spotted to nitrocellulose membranes, let dry 
for ~15 minutes, incubated with blocking buffer and the following steps follow those 
described above for WB. 
 
2.6.  Stability assay (Paper IV) 
Stability of SFTI-1 scaffolded peptides and related peptides (Table 9) was evaluated both in 
human sera and whole-blood. Sera, blood or PBS were incubated at 37 ºC with 200-250 μM 
of each peptide (incubation with blood samples was always performed with gently shaking in 
order to avoid coagulation) at selected time-points (t=0, 10, 60, 180, 330 and 1400 minutes). 
At the end of each time-point, 6 M urea was added to the samples and incubated for 10 
minutes at 5°C. After adding 20% trichloroacetic acid (TCA), samples were centrifuged at 
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13,000 g for 10 minutes. Supernatants were collected and analyzed by liquid 
chromatography-mass spectrometry (Shimadzu LC-10 HPLC system connected to a Thermo-
Finnigan LCQ Deca electrospray ion trap MS). Run was done at 0.3 mL/minute for 30 
minutes using a linear gradient of 5% to 90% acetonitrile in 0.05% formic acid. In order to 
calculate the percentage of remaining peptide, the area under the curve of the peak of each 
peptide at each given time-point of incubation with sera, blood or PBS was calculated and 
compared to the amount of the same peptide at the initial time (t=0). 
 
2.7.  Immunoprecipitation (Paper V) 
Immunoprecipitation is a technique employed for isolation and detection of proteins using a 
specific antibody that recognizes a particular antigen. It enables the purification of non-
abundant proteins in complex matrixes such as sera or plasma therefore, enhancing the 
concentration of the protein target in comparison to the initial sample which facilitates the 
identification. It also enables the study of PTMs and protein-protein interactions. Due to the 
fact that we could not detect HisRS by WB but only using dot-blot, and as a matter of 
confirmation, an IP method was developed. Moreover, we have evidence that a minimum of 
10 ng of HisRS is necessary to be able to visualize the protein when analyzing sera/plasma by 
WB (at least utilizing the methodology available in our laboratory). Considering that not only 
the WB, but also the ELISA ran for HisRS detection in sera/plasma and the recombinant 
protein itself has being troublesome, we concluded that the 3D structure of the protein is 
somewhat sensitive and when bound to a structure such as 96 well plate, it may no longer be 
available for visualization (e.g. due to steric hindrance). We anticipate that differential 
centrifugation of plasma into microparticles and exosomes will provide better visualization of 
the protein (discussed in Conclusions and Future Perspectives section). 
Immunoprecipitation of HisRS from sera samples was undertaken using protein G-coupled 
magnetic sepharose beads that have been incubated with 1 μg/mL commercial anti-HisRS-C-
terminal antibody for 20 minutes. Beads were cross-linked with 50 mM DMP (dimethyl 
pimelimidate dihydrochloride) in 200 mM triethanolamine at pH 8.9, blocked with 100 mM 
ethanolamine pH 8.9 and incubated overnight at 4°C with 10 μL sera diluted in 100 μL TBS 
pH 7.5. Subsequently to several steps of non-harsh wash, proteins were eluted with 4% acetic 
acid and detection was executed by WB using anti-HisRS-C and anti-HisRS N-terminal as 
detection antibodies. 
 
2.8.  Cell culture of myoblasts and myotubes (Paper V) 
In-vitro grown myotubes (derived from myoblasts) are a good representative of adult 
myocytes and can be used as a laboratory tool to study, for instance, the effect of 
autoantibodies or certain drugs in the local inflammatory milieu, fibers contractility and 
muscle weakness related pathways. The study of muscle cell proliferation and differentiation 
is also possible recurring to in-vitro grown myotubes. 
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Figure 12 Satellite cells (previously 
prepared from a muscle biopsy, as 
described in Pandya et al 2015, 
under revision) were expanded in 
collagen type I-coated flasks, using 
DMEM GlutaMax/20% FBS, 
penicillin, streptomycin and 
fungizone containing media. For the 
myoblasts proliferation it is 
important to use cell culture media containing >10% FBS. When confluent, fresh DMEM GlutaMax/20% FBS 
containing media was added and the myoblasts were harvested 24 hours later. In a parallel experiment, 
myoblasts were cultivated in DMEM GlutaMax containing only 2% FBS so they could fuse and form myotubes. 
 
2.9.  Platelet-related experiments (Paper V) 
Platelets experiments were performed in order to investigate HisRS unknown non-
canonical functions (311). Platelet rich plasma (PRP) was obtained from healthy donors 
(n=4) blood, collected in sodium citrate-containing vacutainer tubes and centrifuged at 150 
g for 11 minutes. Serial concentrations of rHisRS (0.05 to 200 pM) or ADP (positive 
control, 1 to 8.6 µM) were incubate with PRP for 15 minutes at RT. Thereafter, PRP-
rHisRS/ADP mixture was incubated with CD62P (P-selectin) antibody for 20 minutes in 
darkness. Platelet activation was assessed by measuring P-selectin expression by flow 
cytometry.  
 
3 In vivo model of pain (Paper II) 
In order to investigate the impact of ACPA in the development of pain that frequently 
precedes joint inflammation in RA patients, affinity purified ACPA (anti-CCP2 IgG, Paper I) 
were injected intravenously in male B10.RIII and BALB/c mice. Animals were also 
systemically injected with monoclonal murinized ACPA antibodies. Further, and with the 
intent of understanding the molecular mechanism responsible for ACPA-induced pain, mice 
were given intra-articular (ankle joint) injections (isoflurane anesthesia was used when 
performing the injections thereof) of CXCL1, CXCL2 (30 ng each or 30 ng in a 1:1 mixture). 
Additionally, mice were injected subcutaneously with CXCR1/2 antagonist (reparixin), twice 
a day, 30 mg/kg/day. After the injections, mice were monitored for mechanical 
hypersensitivity, which can be assessed by calculating the threshold amount of force required 
to withdraw the paw from a given applied stimulus. In order to do that, von Frey filaments 
(373) were used to apply the stimuli in the hind paw and the withdrawal thresholds were 
estimated using Dixon up-down method (374). Heat and cold sensitivity were assessed as 
follows: heat, mice were placed in a temperature controlled container where a radiant thermal 
stimulus is applied from under the glass where the mice are standing (modified Hargreaves 
box (375)); cold, a drop of acetone was applied to the hind paw. After applying the thermal 
stimuli, sensitivity was assessed by measuring the duration of nocifensive behaviour, such as 
lifting, shaking, biting, and licking the paw. Another feature of pain was assessed by 
recording the locomotor activity via monitoring the night activity of the animals, utilizing 
Oxymax/Comprehensive Lab Monitoring System equipped with infrared sensors for 
movement detection in three axes (X, Y and Z). Total movement, ambulation and rearing 
were determined. On the day of sacrifice, organs were collected for later determination of 
inflammation markers and fate of injected antibodies. 
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4 Statistics 
In paper I, Mann-Whitney U test for independent groups was employed in order to determine 
the differences in antibody levels among both the ACPA reactivities in plasma and SF as well 
as in the anti-CCP2 IgGs eluted from the CCP2 column. In paper II, the following statistical 
models were used: Two-way ANOVA to analyze changes over-time and one-way ANOVA 
to address differences in > three groups, both followed by Bonferroni post-hoc test; 
differences between two groups were investigated using Student’s t-test; for arthritis and 
histological scores the Kruskal-Wallis test was used followed by Dunn’s multiple comparison 
post hoc test. In paper III and IV, comparison between competition percentages performed by 
the different ACPA inhibitors was investigated using Student’s t-test. Cutoff values for 
microarray chip data (ISAC system) were calculated as the 98th percentile reactivity among 
the EIRA controls included in the study. All statistical analysis, including calculations of IC50 
values, were performed using GraphPad Prism 6 software. IC50 was considered as defined by 
the International Union of Pharmacology Committee on Receptor Nomenclature and Drug 
Classification: ‘the molar concentration of an antagonist that reduces the response to an 
agonist by 50%’ (376). In Paper V, Spearman nonparametric function was used to search for 
correlations between autoantibodies in BAL and sera (the confidence interval assumed was 
set to 95%). P<0.05 was assumed to denote a significant difference. 
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Figure 13 Schematic illustration of the 
anti-CCP2 IgG purification process 
RESULTS AND DISCUSSION 
1. Affinity purified anti-citrullinated protein/peptide antibodies target antigens 
expressed in the rheumatic joint (Paper I) 
An increased number of studies demonstrate the pathogenic potential of ACPA (97, 194, 199, 
377-379). In study I we developed a new methodology to purify human ACPA from plasma 
and synovial fluid (SF) from patients with RA. The isolation of these autoantibodies was 
intended to acquire unique molecular tools for future studies on the pathobiology of ACPA.  
Using the procedure illustrated in Figure 13 we 
efficiently purified anti-CCP2 IgG from both plasma 
and SF. By first applying the samples on protein G 
columns we isolated total IgGs that were afterwards 
efficiently separated in two fractions, CCP2 eluate 
(anti-CCP2 IgG) and CCP2 flow through (non-CCP2 
reactive IgG, FT), using a CCP2-affinity column. This 
methodology provided high recovery of pure, intact 
and reactive anti-CCP2 IgG. Additionally, it enabled 
the measurement of the protein content of all 
chromatography fractions and thus, a more accurate 
estimation of the concentration and proportion of anti-
CCP2 IgG in both plasma and SF. Although the 
median concentration of anti-CCP2 IgG was more 
elevated (0.2 mg/ml) in plasma in comparison to SF 
(0.06 mg/ml), the proportion of CCP2-reative IgG 
was in fact slightly higher in SF (2.2% compared to 
1.5% in plasma). These observations are in line with a 
recent study whereby a similar technique was utilized 
to isolate anti-CCP2 reactive IgG, and are likewise 
concordant with other antigen-specific IgG responses 
(380-382). Further, SF from four patients revealed a percentage of CCP2-reactive IgG above 
6% of the total IgG pool, whereas in plasma the highest sample registered presented < 4% 
CCP2-reactive IgG molecules. This result suggests a local enrichment and perhaps also local 
production of ACPA in the synovial rheumatic joint, an observation in line with a previous 
work that showed increased titers of ACPA in SF (192), and further sustained by a recent 
study where the authors demonstrated that ~25% of the synovial IgG-expressing B cells are 
CCP2-reactive (76). 
 
Anti-CCP2 IgG collected from the CCP2 column were analysed by in-house peptide ELISAs 
and were demonstrated to contain ACPA of different fine specificities. Namely, CCP2 eluates 
isolated from both plasma and SF reacted against α-enolase (CEP-1; amino acid residues 5-
21), vimentin (Cit-vim; amino acid residues 60-75), fibrinogen α chain (Cit-fib; amino acid 
residues 36-52 and 563-583, the former was not included in the article), and collagen type II 
(Cit-C1; amino acid residues 359-369), demonstrating that CCP2 can act as a surrogate 
marker for different ACPA reactivities. Our data confirms and provides additional evidence 
to a previous study that showed the possibility of eluting fibrinogen-reactive ACPA from 
CCP2 ELISA plates (383). The different composition of ACPA reactivities may account for 
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the distinct CCP2 binding profiles observed for each patient sample after ELISA analysis, 
although the CCP2 eluates were ran at the same concentration. However, no association was 
observed between a specific ACPA reactivity and the CCP2-binding. Interestingly, some 
anti-CCP2 IgG (especially those purified from the SF) presented simultaneous high CEP-1 
reactivity and weaker CCP2-binding. Similar observations were reported by another study in 
which reactive B-cells were described to be more commonly found in SF (76). Although this 
finding may suggest that anti-CEP-1 IgG have low anti-CCP2 affinity, particularly in SF, it 
may simply mean a better CEP-1 ELISA performance, in comparison to the other peptide 
ELISAs. Nevertheless, the CCP2 column efficiently bound all anti-CEP-1 IgGs since no 
reactivity was found in the control FT. The reactivity of CCP2 eluates to different 
citrullinated proteins was confirmed by WB. In addition, we could also demonstrate that anti-
CCP2 IgG bind in-vivo generated citrullinated proteins. 
 
To conclude, in Paper I we developed an efficient method to purify anti-CCP2 IgG from RA 
plasma and SF thus providing molecular tools that can be employed to study ACPA-mediated 
immune responses. This methodology enabled an accurate measurement of CCP2-reactive 
IgG in both fluids and further provided evidence for the use of CCP2 as a surrogate marker 
for several ACPA reactivities. 
 
2. Autoantibodies to citrullinated proteins induce joint pain independent of 
inflammation via a chemokine-dependent mechanism (Paper II) 
Joint inflammation is frequently preceded by arthralgia (joint pain) and patients in remission 
continue to suffer from mild, moderate or severe pain (223, 224). ACPA is often detected 
before clinical onset of RA and predicts development of arthritis in patients with arthralgia 
(70, 384). In paper II we addressed whether ACPA were able to induce pain in mice, 
independent of joint inflammation. 
 
ACPA induces pain-like behaviour 
Intravenous administration of human polyclonal ACPA (anti-CCP2 IgG purified from RA 
sera, Paper I) evoked mechanical hypersensitivity in mice. The reduction in the tactile 
threshold was observed already at day three, and lasted up to 28 days post-injection. ACPA-
injected mice also presented heightened thermal hypersensitivity (both cold and heat) in 
comparison to animals injected with either CCP2 flow through (FT) or saline. Spontaneous 
pain like-behaviour (non-evoked) was evaluated by monitoring the animals total movement, 
directional walking and rearing. Only ACPA-injected mice presented a significant reduction 
in the three parameters addressed. No signs of inflammation or arthritis were detected, 
suggesting that the pain-like behaviour (evoked and spontaneous) is a result of ACPA pro-
nociceptive effect and not due to classic inflammation-related molecules. The same 
experiments were performed with two other ACPA pools, prepared from different RA patient 
samples, in different mouse strains and similar results were obtained, which indicates that 
ACPA-mediated pain is independent of the autoantibodies batch and mouse strain. Murinised 
monoclonal ACPA obtained from synovial fluid B cells from patients with RA evoked 
similar pain like-behaviour as that observed with human polyclonal ACPA. This finding rules 
out the possibility of the induction of pain being the result of an immune response against 
human antibodies. 
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One of the ACPA pools was utilized to investigate if mice developed arthritis in another set 
of experiments. After a single intravenous injection of human purified autoantibodies 
followed (three hours later) by an intraperitoneal injection of lipopolysaccharide no arthritis 
was registered (data not shown). Mice injected with a cocktail of anti-collagen antibodies 
developed transient arthritis. Additional experiments need to be performed to further explore 
whether or not ACPA possess arthritogenic potential. 
 
The location of antibodies in mice organs was evaluated seven days post-injection. ACPA 
were specifically found in joint, bone marrow, skin, DRG, adipose tissue and spleen whereas 
RA non-CCP2 reactive IgG and IgG purified from healthy donors presented a similar 
distribution, yet broader. These observations suggested that ACPA may have preferential 
organ targets, which may give clues on the pro-nociceptive mechanism of action. 
Furthermore, these findings bring out the potential to identify novel non-described ACPA 
targets. 
 
ACPA-pain mediated mechanisms 
The direct effect of ACPA in primary peripheral neurons was investigated as a possible 
ACPA-pain mediated mechanism. Primary cultures of mouse DRG were stimulated with 
ACPA or FT (at 1 µg/ml) followed by KCl (50 mM, positive control) stimulation at the end 
of the experiment. The intracellular concentration of Ca
2+
 was measured in order to assess 
cells that were able to depolarize (thus, capable of generating an action potential). From the 
total number of cells utilized in the assay 80% was activated by KCl and from those only 
2.5% and 1.7% were activated in response to ACPA and FT, respectively. Additionally, 
ACPA did not induce inward currents in small nociceptive neurons. These observations lead 
us to conclude that ACPA does not induce Ca
2+ 
flux or inward current, which indicates lack 
of direct modulation of neuronal excitability. 
 
ACPA-injected mice did not present the classical signs of inflammation. Histological 
evaluations showed no cell infiltration or hyperplasia in the synovia. In addition, mRNA 
analysis showed no significant differences between levels of certain chemokines (CXCL5, 
CCL2), cytokines (TNF, Il-1 and IL6), matrix metalloproteinases, inflammatory enzymes 
(Cox2), and mast cell proteases in ankle joint lysates from ACPA-injected mice in 
comparison to saline –administered animals. Interestingly, mRNA levels of chemokines 
CXCL1 (human IL-8 analogue) and CXCL2 were found elevated in the ankle joint of ACPA-
injected mice. No difference was observed in the mRNA levels of both CXCL1 and CXCL2 
in FT and saline-injected mice.  
Immunohistochemistry analysis revealed that ACPA specifically binds non-permeabilised 
CD68
+
 cells which, due to location and morphology, appear to be osteoclasts. Thereafter, 
mouse osteoclasts were treated with ACPA or FT and the release of human IL-8 analogs 
(CXCL1/2) was examined. A significant increase in the levels of CXCL1 was found in 
supernatants from ACPA-treated mouse osteoclasts whereas no difference was observed in 
supernatants from FT or saline-treated osteoclasts. Immunostainings also showed that, in the 
bone marrow, ACPA binds CD68
+
cells located near the calcitonin gene related peptide 
(CGRP)-positive sensory fibers, known to transmit pain/nociceptive sensation. 
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In order to investigate whether ACPA induces pain-like behaviour via CXCL1/2 mechanism, 
additional in vivo experiments were performed. Previous studies demonstrated that CXCL 
chemokines can induce pain-like behaviour (385-388). In study II, the injection of either 
CXCL1/2 alone or CXCL1 and CXCL2 together evoked a rapid mechanical hypersensitivity 
(significant decrease of tactile threshold within two hours post-injection that lasted at least 24 
hours). Mice injected with the monoclonal ACPA D10 and B2 were treated with CXCR1/2 
antagonist (reparixin) for six consecutive days. ACPA-induced mechanical and thermal 
hypersensitivity was partially reversed by the treatment with reparixin. Control antibody and 
reparixin itself did not evoke hypersensitivity. 
 
Taken together, our data suggest that ACPA induces a pain-like behaviour through binding to 
CD68
+
 osteoclasts and leading to secretion of CXCL1, which in turn activates neighboring 
CXCR2 expressing sensory nerves. This mechanism provides evidence for the role of ACPA 
mediating pain in those seropositive patients that although successfully treated for 
inflammation still report pain. In addition, the presence of certain circulating ACPA before 
clinical onset may explain the joint pain in these individuals (384, 389, 390). Additionally, it 
appears that distinct polyclonal and monoclonal ACPA induce pain differently. One possible 
explanation is the different fine specificities ACPA encompass. In Paper IV we describe the 
purification and characterization of a sub-group of citrullinated-fibrinogen reactive ACPA 
that will in the future be utilized to address whether certain ACPA fine specificities (e.g. 
fibrinogen) are indeed responsible for clinical phenotypes such as non-inflammatory 
mediated pain in RA. 
 
3. Targeting of human ACPA using fibrinogen-derived peptides (Paper III and IV) 
We have previously identified endogenously citrullinated fibrinogen peptides in synovial 
tissue from patients with RA (372): within the α chain - Arg573Cit (563-583) and Arg591Cit 
(580-600), referred to as Cit573 and Cit591; within the  chain - Arg72Cit (62-81), and 
Arg74Cit (62-81), referred to as Cit72 and Cit74 (Table 8 methods section).  
 
Endogenously citrullinated fibrinogen peptides constitute autoantigens in RA (Paper III) 
Both the citrullinated and non-modified version of these peptides were placed onto a 
chemically modified glass slide and ACPA response was evaluated by incubating the 
peptides with sera from RA patients (EIRA cohort). These peptide microarray experiments 
revealed that ~50% of the patients sera (n=927) tested were positive for at least one of the 
four peptides whereas <2% of healthy controls presented a weak response (the diagnostic 
specificity for anti-CCP2 was 98.4%). Within the CCP2-positive population, 65% and 15% 
of the patients were positive for the peptides Cit573 and Cit59, respectively; 35% and 53% of 
the patients were positive for Cit72 and Cit74, respectively. Within the anti-CCP2 negative 
RA group, Cit72 and Cit591 held the highest reactivity with a percentage of 8.4% and 6.1%, 
respectively; Cit573and Cit74 displayed lower reactivity, 5.5% and 4.4%, respectively. These 
observations are in line with recent studies showing reactivity against citrullinated peptides in 
the CCP-negative RA population (391, 392). Previously, these peptides were tested in a pre-
RA cohort (180). Notably, increased titres of anti-Cit591 and anti-Cit72 antibodies were 
observed earlier in the disease course, which suggests a possible involvement in the clinical 
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onset. On the other hand, anti-Cit573 and anti-Cit74 autoantibodies were elevated at/after the 
clinical onset, suggesting instead a possible part in disease progression. 
 
Anti-CCP2 IgG are inhibited by fibrinogen-derived peptides (Paper III and IV) 
The capacity of Cit573, 591, 72 and 74 to block human ACPA was evaluated in a set of 
competition assays (Paper III). After incubating different pools of affinity purified human 
anti-CCP2 IgGs (ACPA or aCCP2 IgG pool I and II) with increasing amounts of each 
citrullinated peptide (or non-modified control), the remaining anti-CCP2 reactivity was 
measured and the blocking capacity estimated. 
 
Cit573 was the peptide that presented the best blocking capacity by inhibiting up to 84% of 
aCCP2 IgG (pool I) present in the assay. Cit591 followed displaying a blocking percentage 
of 63%. Peptides from the  chain (Cit72 and Cit74) exhibited lower aCCP2 IgG inhibition 
in comparison to Cit573 and Cit591, 35 and 26%, respectively. The IC50 for each peptide was 
estimated in order to provide additional information on the inhibition capacity. Concordant 
with the best dose-response curve, Cit573 registered the best IC50, 59 µM, compared to 
Cit591 which was calculated as 194 µM. 
The enhanced aCCP2 IgG blocking capacity after mixing Cit573 and Cit591 (91%) suggests 
that the pool of aCCP2 IgG is also composed of non-cross-reactive antibodies, albeit the high 
blockade percentage exerted by the single peptides. This observation extends our findings in 
paper I where we described that anti-CCP2 IgG purified from distinct patients bind 
differently to CCP2 and other ACPA fine specificities. The same experiment was performed 
utilizing autoantibodies purified from a second pool of RA plasma as well as from a pool of 
eleven SF samples. Fifty per cent of aCCP2 IgG pool II was inhibited by both Cit573 and 
Cit591 with an IC50 of 548 µM and 412 µM, respectively. In paper III only results regarding 
aCCP2 IgG pool I and II were presented, however, the inhibition percentage displayed by the 
peptides when incubated with the antibodies purified from SF mimicked that observed for 
aCCP2 IgG pool II. 
 
Linear truncated and cyclic versions of the peptide Cit573 (also named [Cit573]fib(563-583), 
Table 9 in methods) were designed in order to assess whether these new structures improve 
ACPA blocking capacity. Notably, the cyclic version of Cit573 (Cit573Cyc, 
c[Cit573]fib(563-583)) blocked ~90% of all antibodies present in the assay regardless the 
pool tested (IC50 of 28 and 71 µM for aCCP2 IgG pool I and II, respectively). Amino acids 
located on both extremities of the linear peptide appear not to influence the binding capacity 
of the truncated peptides (Cit573Lin1, [Cit573]fib(566-580) and Lin2, [Cit573]fib(567-577) 
in comparison to the full length peptide ([Cit573]fib(563-583)). Truncated [Cit573]fib(566-
580) peptide blocked 75% of aCCP2 IgG pool I (IC50 51 µM) and 47% of aCCP2 IgG pool II 
(IC50 186 µM); Truncated [Cit573]fib(567-577) peptide blocked 69% and 40% of aCCP2 
IgG pool I and II, respectively (IC50 123 and 105 µM). 
 
The concept of neutralizing circulating autoantibodies has been explored in an animal model 
of autoimmune cardiomyopathy whereby anti-1-adrenergic receptor (1AR) antibodies 
were shown to mediate myocardial damage. A cyclic peptide (COR-1) that mimics the main 
epitope of 1AR neutralized anti-1AR antibodies and prevented myocardial injury, and 
furthermore reverted dysfunction of the heart when administered to rats once a month in the 
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course of 3 to 6 months (366, 393, 394). Besides peptides, other small molecules such as 
aptamers have been tested in animal models of SLE and shown to neutralize anti-dsDNA and 
thereby prevent autoantibody-mediated renal injury (395). Likewise, aptamers were also 
demonstrated to neutralize anti-1AR antibodies purified from patients suffering from 
cardiomyopathies (396). 
 
Development of a high binding ACPA inhibitor – SFTI-1 scaffold opportunity (Paper IV) 
In paper IV we further developed the conception of an ACPA blocker. The purpose of such a 
compound would be to block ACPA in patients, preventing chronic pain and other 
debilitating symptoms of RA (365). Figure 16 (under conclusions and future perspectives 
section) illustrates the strategy. We designed a new ACPA blocker which specifically targets 
anti-Cit573 autoantibodies (Paper IV). This new molecule comprises the truncated version 
[Cit573]fib(566-580) (Table 8 and 9, Figure 14) linked to the sunflower trypsin inhibitor-1 
(SFTI-1). In addition to the required specificity of this blocking compound (termed 
s1[Cit573]fib(566-580)), the stability and non-cytotoxicity are major concerns that we 
overcame by using the cyclic plant-derived SFTI-1. The circular peptide backbones and the 
presence of disulfide bond(s) provide these scavenger great stability. In fact, the ability SFTI-
1 holds to accommodate bioactive sequences within its three-dimensional framework, and 
simultaneously keep the stability, has been demonstrated (397, 398). SFTI-1 appears to be 
safe, with no immunogenic or cytotoxic properties reported (399, 400). 
 
As described in paper III, [Cit573]fib(563-583) linear truncated versions [Cit573]fib(566-
580) and [Cit573]fib(567-577) blocked ~70% of aCCP2 IgG from pool I and <50% of 
aCCP2 IgG pool II (Paper IV). Cyclic (c) [Cit573]fib(563-583) reach up to 90% aCCP2 IgG 
inhibition of both pools but when [Cit573]fib(566-580) was head-to-tail cyclized 
(c[Cit573]fib(566-580)) the blocking capacity marginally decreased (86% and 72% 
inhibition of aCCP2 IgG pool I and II, respectively). Interestingly, the arginine 
(c[Arg573]fib(566-580)) and an alanine 
(c[Ala573]fib(566-580)) control versions displayed 
up to 50% aCCP2 IgG inhibition. The amino acid 
residues flanking the citrulline residue have a high 
impact in the binding affinity to the autoantibodies 
possibly because of the adopted unstructured 
conformation, as it was observed in the NMR studies. 
Although mainly random, the amino acids that flank 
citrulline in several known ACPA epitopes (e.g. 
within CEP-1, Cit-vim and Cit-fib) appear to be 
preferentially small and rather neutral (401).  
 
S1[Cit573]fib(566-580) acquired improved stability 
both in whole blood and serum in comparison to the 
linear and cyclic counterpart versions. Above 90% of 
s1[Cit573]fib(566-580) was retained in blood after 
five hours whereas the linear peptides were degraded 
after one hour. In the competition assay, 
s1[Cit573]fib(566-580) was able to block 79% of 
Figure 14 Sequences of the grafted and 
native peptides and a schematic of the 
ACPA inhibitor design strategy. 
49 
 
aCCP2 IgG pool I with an IC50 of 20 μM. A lower percentage of antibodies was blocked 
when testing aCCP2 IgG pool II (61%, IC50 of 87 μM) as it was shown for all the other 
peptides. 
 
Optimizing s1[Cit573]fib(566-580) for ACPA purification and improved affinity (Paper IV) 
In order to facilitate the binding of peptides to affinity chromatography columns and ELISA 
plates the lysine mutant s2[Cit573,Arg575]fib(566-580) was designed. 
S2[Cit573,Arg575]fib(566-580) was coupled to a NHS-activated affinity column and utilized 
to purify Cit573-reactive autoantibodies. Approximately 0.33% of total IgG from RA patients 
(average concentration of 32 µg/mL) was found to react against [Cit573]fib(563-583). These 
autoantibodies were used in experiments that enabled a more accurate measurement of the 
blocking capacity and binding affinity of scaffold peptides.  
In s2[Cit573,Arg575]fib(566-580) the insertion of a lysine in the secondary loop of SFTI-1 
disrupted the β hairpin conformation which led to a decreased stability in solution in 
comparison to the original s1 scaffold. S2[Cit573,Arg575]fib(566-580) rapidly degraded to < 
80% after three hours of incubation in both blood and serum. Therefore, a new mutant, 
s3[Cit573,Arg575]fib(566-580), was designed in which the arginine of the structural loop 
was substituted by a lysine. This peptide showed structural similarities to s1[Cit573]fib(566-
580) and as a consequence improved stability in comparison to mutant s2. Forty nine per cent 
of s3[Cit573,Arg575]fib(566-580) remained after three hours incubation in blood.  
 
The blocking capacity of the new mutants was explored in the competition assay in which 
both the aCCP2 IgG pool I and aCit573 IgG were tested. S3[Cit573,Arg575]fib(566-580) 
was the mutant with the best performance since 40 nmol of the compound blocked 88% 
aCCP2 IgG. The isolation of ACPA subtypes (aCit573 IgG) and their use in the competition 
assay demonstrated an improvement in the blocking efficiency of s3[Cit573,Arg575]fib(566-
580 (97% inhibition) in comparison to aCCP2 IgG blockade. S2[Cit573,Arg575]fib(566-580) 
blocked 44% and 66% of aCCP2 IgG pool I and aCit573 IgG, respectively. Binding affinity 
assays (fluorescence correlation spectroscopy) demonstrated and confirmed that the mutant 
s3[Cit573,Arg575]fib(566-580) binds aCit573 IgG with high affinity (Kd=2 nM). Kd for 
aCCP2 IgG was registered 17 nM. 
 
In summary, paper III and IV provide proof-of-principle that affinity purified ACPA and 
specific ACPA fine specificities (aCit573 IgG) can be neutralized in vitro by stable molecules 
structurally based on endogenously citrullinated fibrinogen peptides. Anti-Cit573 IgG bind 
scaffolded fibrinogen peptides with high affinity. Furthermore, we propose that such 
molecules may be applied for development of potent ACPA blocking compounds. 
 
4. Characterization of extracellular histidyl-tRNA synthetase in myositis (Paper V) 
Histidyl-tRNA synthetase (HisRS or Jo1) is one of the most prevalent autoantigens in 
myositis. Autoantibodies that target this protein (anti(a)-Jo1/aHisRS) are present in a large 
percentage of patients with myositis as well as in patients with anti-synthetase syndrome, 
characteristic clinical phenotype that involves organs other than the muscle (e.g. the lung) 
(276, 285, 293). 
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HisRS is present in circulation – Lung and muscle as possible sources of extracellular HisRS 
In paper V we described the presence of HisRS in extracellular compartments such as serum, 
plasma and BAL. Patients with myositis presented elevated levels of HisRS in sera in 
comparison to HC and RA patients. Furthermore, patients with aJo1+ myositis appear to have 
higher amount of HisRS in circulation in comparison to aJo1- population. 
Extracellular HisRS was also detected in BAL fluid. Interestingly, a strong signal dictating 
the presence of HisRS was found in HC (and sarcoidosis patients) contrary to what was 
observed for healthy sera in which very little protein was detected. This observation led us to 
speculate whether HisRS, known to be a cytoplasmic enzyme, could additionally be present 
in extracellular compartments in physiological conditions. Furthermore, we questioned if 
HisRS detected in circulation could be originated and released from the lung under unique 
circumstances such as chronic inflammation, as observed in myositis. One possible source 
within the lung could be the alveolar epithelium known to express HisRS in the native and 
granzyme B proteolytic sensitive conformation (this conformation is recognized by sera from 
aJo1+ patients and thus, may be autoantigenic) (328). Pneumocytes, alveolar macrophages 
and endothelial cells in the bronchus have also been shown to express HisRS (402). 
Additional evidences suggest a connection between HisRS and the lung in an autoimmune 
context: 1) association between aJo1 and ILD (403, 404); 2) aJo1 associates with HLA 
DRB1*03 genetic background and smoking (57); 3) patients with HLA DRB1*03 genotype 
display selective T cell-receptor V-gene usage in BAL and muscle (333). 
 
A possible additional source of systemic HisRS in myositis could be the muscle. Previous 
studies strikingly demonstrated an increase of HisRS expression on muscle fibers undergoing 
regeneration, rather than in fully differentiate myotubes (98). In fact, HisRS protein levels in 
healthy muscle are very low, compared to muscle from myositis patients (98, 402). As it was 
recently described that recombinant HisRS and a HisRS splice variant (lacking the entire 
catalytic domain but still recognized by aJo1+ sera) are secreted from mouse C2C12 
myoblasts (310) we speculated whether regenerating muscle fibers were the origin of 
extracellular HisRS found in the sera of patients with myositis. The WB analysis of muscle 
homogenates from several different myositis patients revealed significant expression of 
HisRS. Additionally, myoblasts and low-grade differentiating myotubes derived from a 
dermatomyositis patient also showed HisRS protein expression. However, no HisRS could be 
detected in the supernatants collected from myoblasts treated with TNF-α. Additional 
experiments are required in order to further dissect the muscle as the origin of exogenous 
HisRS. 
 
The presence of a cytoplasmic protein such as HisRS in extracellular comportments is also 
supported by a growing body of evidence demonstrating the secretion of several aaRS by 
different types of cells. Tyrosyl-RS and threonyl-RS, both autoantigens in myositis, were 
described to be secreted by endothelial cells (405, 406). Threonyl-RS was in fact shown to be 
secreted by ovarian cancer cells and to be present in sera of cancer patients (407). Glycyl-RS, 
another autoantigenic aaRS described in myositis, was detected in healthy sera and it was 
found to be released by macrophages (408). 
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Extracellular HisRS and the ‘X-factor’ 
The presence of HisRS extracellularly was verified by performing pre-adsorption 
experiments. BAL fluid and sera were placed onto nitrocellulose membranes and incubated in 
parallel with either anti-HisRS-N-terminal antibody or with the anti-HisRS-N-terminal 
antibody previously bound to an excess of recombinant HisRS. Although we could confirm 
that HisRS was indeed the protein detected in BAL fluid and sera, we came across an 
unexpected finding (Figure 15a, right panel). 
 
 
 
Figure 15a HisRS is present in circulation and in BAL fluid. The pre-adsorption control experiments reveal the 
presence of a ‘HisRS enhancing binding factor’ translated by the intense black dot mainly observed in BAL 
fluid and sera from myositis patients. Numbers 1 to 8 represent different individuals. Myos, myositis; S, sarcoidosis; HC, 
healthy controls; BAL, bronchoalveolar lavage fluid. 
 
In order to address the nature of the ‘enhancing binding factor’ we first sought for the 
existence of IC comprising HisRS and IgG linked to C1q, but no C1qIC could be detected in 
BAL from either aJo1+ or aJo1- myositis BAL. Noteworthy, IgG-depleted BAL presented a 
similar black signal compared to that observed in the original BAL suggesting that the 
presence of anti-Jo1 IgG autoantibodies may not solely contribute to the enhancing binding 
factor (Figure 15b). 
 
 
Figure 15b Possible origins of HisRS enhancing binding factor. i, normal protocol; ii, pre-adsorption 
protocol. 
 
Subsequently, we investigated the presence of anti-Jo1 isotypes other than IgG. Both aJo1 
IgA and aJo1 IgM could be simultaneously detected in sera and BAL fluid from at least three 
of the eight myositis patients analysed. The presence of autoantibodies in BAL fluid has been 
previously described. ACPA were revealed to be enriched in the lungs of RA patients (83). 
Furthermore, early ACPA+ RA individuals (with no lung disease) were recently found to 
contain germinal centers, B cells and plasma cells in the lung (84). Our observations of anti-
Jo1 autoantibodies in BAL fluid from myositis patients are in line with these studies. 
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The BAL fluid was subjected to additional experiments in order to address the presence of 
autoantibodies other than aJo1 and therefore, find alternative explanations for the nature of 
the binding factor. Notably, among the different antibody reactivities tested (anti- Ro60/SSA, 
La/SSB, Sm, Sm RNP, U1 RNP, Scl-70, dsDNA, CENPB, RIBO, pm-scl, and PCNA) only 
antibodies targeting TRIM21 (Ro52) could be detected in BAL from myositis patients. 
Moreover, a positive correlation between the presence of aTRIM21 IgG and aJo1 IgG in 
BAL was found (p= 0,007; Spearman 2= 0,881). A summary of the findings concerning 
HisRS and BAL fluid from myositis patients is listed in Table 10. Of note, the three patients 
positive for the anti-Jo1 isotypes also contain aTRIM21 IgG, ILD, the binding factor and 
absence of extracellular HisRS. All patients positive for aJo1 IgG were diagnosed with ILD.  
 
Table 10 Information on diagnosis of ILD and presence of anti-Jo1 isotypes, anti-TRIM21 
IgG, extracellular HisRS and ‘enhancing binding factor’ in BAL from patients with myositis. 
Myositis patient ILD
*
 aJo1 IgG aJo1 IgA aJo1 IgM aTRIM21 IgG HisRS Binding factor 
1 + + + + + - + 
2 + + + + + - + 
3 - - - - - + - 
4 + + + + + - + 
5 + + - - - + + 
6 - - - - - - - 
7 + + - - - + - 
8 - - - - + + - 
* ILD, Interstitial lung disease; + positive/presence; – negative/absence. 
 
Although at this point we have no definitive proof for the genesis of the enhancing binding 
factor, it is tempting to speculate whether a molecular interaction between HisRS and 
TRIM21 may be the root cause. Both these two molecules have been suggested to be targets 
of a coupled immune response and to co-occur in myositis (409). In addition, patients with 
ASS and with aTRIM21 IgG were shown to have worse ILD in comparison to those patients 
that did not present aTRIM21 IgG (410). Additional experiments are required in order to 
confirm the origin of HisRS enhancing binding factor. 
 
Extracellular HisRS and a novel non-canonical function 
Platelets are key mediators of the immune response and inflammation. For instance, platelets, 
known to express TLR4 and 2, were shown to trap bacteria in liver sinusoids and pulmonary 
capillaries by inducing NETS via TLR4 (411). Interestingly, HisRS has been attributed a role 
in triggering innate immunity in myositis through TLR4 and 2 (via common MyD88 
signaling cascade) (331, 332). Doubled knockout mice for TLR4 and 2 presented reduced 
inflammation that had been induced by HisRS immunization (332). Moreover, the generation 
of class-switched autoantibodies in a murine model of myositis induced by intramuscular 
injection of recombinant HisRS was dependent on TLR4 (412). Raynaud’s phenomenon, 
common clinical feature of ASS, was found to be associated with platelet-derived 
microparticles and further, with enhanced platelet activation and aggregation (413-415). In 
line, patients with DM present high titers of platelet-derived microparticles (416). As a result 
of detecting HisRS exogenously, we sought for non-canonical functions namely, the effect of 
HisRS on platelets and discovered that HisRS activates platelets (by increasing CD62P 
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expression) in a dose-response manner at low picomolar concentrations. The discovery that 
another aaRS (tryrosyl-RS) acts as a thrombopoietic agent supports our findings and 
collectively suggests that aaRS may display important platelet-related functions. 
 
Anti-Jo1 autoantibodies 
Recombinant human HisRS was employed to prepare an affinity column for purification of 
autoantibodies targeting HisRS from human sera (aJo1). The methodology utilized follows 
the scheme published in Paper I (Figure 13, results and discussion section). Anti-Jo1 IgG 
were estimated to constitute 1.5% of the total myositis IgG pool, existing in an average 
concentration of 180 µg/ml in myositis sera from aJo1+ patients. This values fall in the range 
of anti-CCP2 IgG reactivity in RA patients, as we similarly demonstrated in Paper I.  
 
In conclusion, paper V provides further evidence for a role of HisRS in myositis with lung 
involvement, which may be due to: 1) the presence of the protein that once in extracellular 
compartments such as serum and BAL fluid may be more amenable to undergo PTMs; 2) a 
coupled immune response between HisRS with TRIM21. Furthermore, we suggest that when 
exogenously HisRS may perform additional non-canonical functions such as platelets 
activation. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
This thesis was devoted to the study of two chronic autoimmune diseases. RA and myositis 
are complex, multifactorial conditions that express heterogeneous clinical presentations. In 
both cases, patients can be grouped in seropositive or seronegative according to the existence 
of certain circulating autoantibodies. Particularly, antibodies targeting citrullinated 
proteins/peptides (ACPA) are characteristic of a major population of patients with RA 
displaying more erosive disease; anti-Jo1 (HisRS) autoantibodies are typically associated 
with myositis and together with seven other so far described, aaRS, further classify a sub-
group of patients with ASS. The studies performed in this thesis have contributed to a better 
understanding of the auto-antibody/antigen related molecular mechanisms underlying RA 
and myositis. 
 
The development of a methodology to purify autoantibodies (Paper I) opened a full new 
array of possibilities to study the autoimmune response engaged by ACPA and anti-Jo1 IgG 
in patients with RA and myositis, respectively. This method was employed throughout my 
PhD, providing me with autoantibodies of different reactivities which enabled the studies 
presented in the five papers that constitute this thesis. Purified ACPA anti-CCP2 IgG) have 
been additionally utilized to explore their pathogenic role in bone destruction (379), synovial 
fibroblasts migration (417), identification of novel targets (418) and glycosylation patterns 
(219). In Paper I we demonstrated that CCP2 acts as a surrogate antigen for a variety of 
ACPA fine specificities and we showed that those ACPAs bind to in vivo and in vitro 
generated citrullinated proteins. The methodology developed herein, provided an accurate 
measurement of ACPA concentration and proportion in plasma and SF of RA patients. 
 
It would be interesting to address the correlation between individual ACPA levels (and also 
fine specificities) and the treatment the patients underwent at time of sample retrieval. Such 
an assessment may offer insights into which therapies can successfully be applied to ACPA+ 
patients. It would also be interesting to investigate new possible ACPA targets in the 
synovial tissue. In Paper I we demonstrated ACPA binding to synovial tissue and SF cells. 
On-going two-dimensional gel electrophoresis and mass spectrometry studies may soon 
provide additional clues on novel ACPA autoantigens (372). 
 
The evidence that purified human ACPA induces pain independent of inflammation (Paper 
II) provides explanatory clues to the molecular mechanisms underlying the inflammation 
and transmission of pain in RA. Furthermore, the occurrence of ACPA before signs of 
arthritis could explain the joint pain that sometimes precedes clinical onset. Interestingly, we 
discovered that ACPA does not directly activate primary sensory neurons, but rather seems 
to induce pain through binding to CD68
+
 osteoclasts in the joints, leading to release of 
CXCL1 and consequently activation of nearby sensory neurons.  
 
Purification of the different known ACPA fine specificities and injection in mice may help to 
understand which populations of ACPA are responsible for inducing pain-like behaviour. 
Although no concrete proof is available, certain ACPA reactivities seem to occur earlier than 
others (anti-Cit591 and anti-Cit-vim 60–75) (180). Other ACPA reactivities would also be of 
value for testing in the in vivo setting (anti-Cit573, anti-CEP-1 or anti-CitC1). It would be 
very interesting to investigate whether ACPA induced pain-like behaviour could be reverted 
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or prevented by using specific blockers. Such strategy was the founding idea of Paper III and 
IV. 
 
The development of new blocking molecules capable of neutralizing pathogenic ACPA 
introduces a new therapeutic approach intended to specifically target ACPA+RA patients. 
The concept of personalized therapies has been increasingly suggested due to the possibility 
to treat patients more specifically (that is, targeting molecular mechanisms known to be 
responsible for the disease presentation in a specific group of individuals) and with less side-
effects. 
 
Paper III demonstrates the autoantigenic potential of four citrullinated fibrinogen peptides, 
previously shown to be endogenously citrullinated (372). Those antigens were tested for the 
capacity to block purified human ACPA (aCCP2 IgG), and [Cit573]fib(563-583) peptide 
revealed to be a good candidate. In order to improve ACPA specific binding and blood 
stability, a shorter linear version of [Cit573]fib(563-583) was inserted into a scavenger 
(SFTI-1, Paper IV). The new molecule, s1[Cit573]fib(566-580), proved to be more stable 
than both the linear counterpart and the cyclic versions of [Cit573]fib(563-583). In addition, 
the arginine version, s1[Arg573]fib(566-580), did not display significant aCCP2 IgG 
binding. The development of an additional mutant, s2[Cit573,Arg575]fib(566-580), provided 
a new tool for the successful purification of anti-Cit573 autoantibodies from a mixture of 
total RA IgG. These autoantibodies will be injected in mice and the pain-like behaviour will 
be assessed, as performed for total aCCP2 IgG in Paper II. Additionally, the mutant 
s3[Cit573]fib(566-580) will be tested for the capacity to reduce and/or prevent pain in 
aCCP2 IgG -injected mice (as well as for anti-Cit573 IgG, in case this reactivity would 
induce pain). Figure 16 illustrates the treatment strategy we suggest based on the findings 
from Paper III and IV. 
 
Autoantigens provide crucial clues for the understanding of the molecular mechanisms that 
govern autoimmune diseases such as RA and myositis. In this thesis special emphasis was 
given to HisRS, the major autoantigen known for myositis. In Paper V we demonstrated the 
presence of HisRS in extracellular components such as serum, plasma and BAL fluid. 
Patients with myositis presented higher levels of circulating HisRS in comparison to HC and 
RA patients. Interestingly, BAL fluid from HC and sarcoidosis patients presented significant 
amounts of extracellular HisRS. 
HisRS is a cytoplasmic enzyme involved in the protein synthesis. The presence of this 
enzyme outside the cell in physiological conditions is indicative of additional novel non-
canonical functions, similar to what has been described for other synthetases (311). It has 
been demonstrated that proteins such as aaRS underwent evolutionary pressure over the 
phylogenetic tree. aaRS from higher eukaryotic organisms were appended additional 
domains not found in prokaryotes (311). For example, the WHEP domain of HisRS is known 
to contain the main epitope target of anti-Jo1 autoantibodies (313, 321) and is not present in 
bacteria and in lower eukaryotes. This domain was demonstrated to be essential for HisRS 
chemoattractant properties (99) and it contains a granzyme B cleavage site that originates a 
proteolytic structure known to be highly expressed in the lung (328). 
We herein show that HisRS activates platelets in a dose-response manner. The mechanism of 
action is so far unknown. One possibility may be through activation of TLR receptors since it 
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is acknowledged that platelets express those receptors and HisRS was shown to engage in 
innate immunity processes via TLR2 and 4 (331, 332). 
 
BAL fluid from patients with myositis revealed the presence of an unknown ‘enhancing 
binding factor’. In an attempt to understand the meaning and origin of such factor we 
discovered that BAL fluid from patients with myositis contain anti-Jo1 IgG, IgA and IgM. In 
addition, anti-TRIM21 IgG were also found in BAL (and sera) from the same patients and 
were further shown to be positively associated with anti-Jo1 IgG. No C1qIC could be 
detected in the BAL fluid, ruling out the possibility of IC, comprising C1q, aJo1 and HisRS, 
as the enhancing factor. These findings support a previous study in which the authors raised 
a possible coupled immune response involving both molecules, HisRS and TRIM21 (409). 
Although these findings do not directly explain the origin of the binding factor, they 
nevertheless provide additional evidence for the role of HisRS (and to some extent TRIM21) 
in mediating the development of autoimmunity in patients with myositis and lung 
involvement. Figure 17 illustrates one current hypothesis for the initiation and development 
of myositis autoimmunity. 
 
We speculated whether circulating HisRS originates from the lungs (as it was found in BAL 
fluid). However, other possible sources should be taking into consideration. One possibility 
may well be the regenerating muscle, known to express elevated amounts of autoantigenic 
HisRS in myositis (98). Our data do not support the muscle as the point of exogenous HisRS 
origin. However, additional studies are required to fully answer this question. One interesting 
approach to investigate the cellular origin of exogenous HisRS would be to determine 
whether circulating HisRS is bound to microparticles. If so, the origin of those microparticles 
may help us discover from which cells HisRS is been released. In vitro grown myotubes may 
be utilized in order to investigate if HisRS is released from the cells in response to different 
types of stimuli (e.g. other cytokines), not herein investigated. 
 
The development of a quantitative method (e.g. ELISA) to determine exact circulating 
HisRS values is of major importance. Preliminary data (not shown) suggest that HisRS 
values in serum from patients with myositis may vary overtime. To assess a possible 
correlation between auto- antibody/antigen levels and whether there is as an association 
between those and the therapies administered to the patients may not only give insight into 
the immune mechanism behind aJo1+ myositis but it may also be used as a future biomarker.  
 
In paper V anti-Jo1 autoantibodies were purified and briefly characterized. Similarly to what 
we have found for ACPA, aJo1 constitute ~1.5% of the total IgG pool in sera from patients 
with myositis. These autoantibodies are currently being tested in cell cultures of myoblasts 
and myotubes with the purpose to characterize possible pathogenic effects (e.g. induction of 
cell death, release of proinflammatory cytokines and modulation of muscle contractility 
machinery). 
 
In conclusion, this thesis has contributed to the knowledge underlying RA and IIM 
immunological mechanisms and provided the first steps for the development of an 
autoantibody-targeted therapy. 
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Figure 16 In the hypothetical model presented for CCP+ RA, we propose the neutralization of citrullinated-fibrinogen reactive autoantibodies (Anti-Cit-Fib Ab) 
and B cells (Cit-Fib-reactive B cell) as a complementary strategy to treat this subset of patients. 
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Figure 17 Based on the findings described in this thesis we added new pieces of evidence to the hypothesis of 
lungs as the site of autoimmune origin in myositis. HisRS is physiologically present in extracellular 
compartments (intracellular (i) HisRS expressed in lung epithelial cells; extracellular (ex) HisRS present in 
BAL for instance). In adverse conditions (e.g. inflammation caused by smoking or viral infection) HisRS may 
undergo post-translational modifications leading to a tolerance breach and consequent local production of 
autoantibodies of various isotypes. 
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